Biophytis

Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. The company's drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

Elon Musk, CEO of Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>), clarified when the automaker would start accepting Bitcoin (CRYPTO: BTC) for its vehicles again in response to a tweet of one of the biggest crypto publications, Cointelegraph.
What Happened: Earlier today, Elon Musk said Tesla would only get back to accepting the cryptocurrency when there&rsquo;s &ldquo;a clear confirmation of reasonable (~50%) clean energy usage.&rdquo;&nbsp;
<blockquote class="twitter-tweet">This is inaccurate. Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market.
When there&rsquo;s confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1404132183254523905?ref_src=twsrc%5Etfw">June 13, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The tech tycoon was replying to a tweet published by Cointelegraph regarding Sygnia CEO&#39;s latest comments.&nbsp;
Magda Wierzycka, CEO of a financial services company Sygnia, heavily criticized Musk&rsquo;s &ldquo;recent activity on social media&rdquo; and the subsequent &quot;influence on crypto markets.&quot;
&ldquo;The [Bitcoin] volatility we have seen is an unexpected function of what I would call market manipulation by Elon Musk. If that happens to a listed company, he would be investigated and severely sanctioned by [the] SEC,&rdquo; said Wierzycka in a recent interview with&nbsp;the Money Show.
Why It Matters:&nbsp;In May, Musk announced that he <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21269336/elon-musk-might-reconsider-his-stance-on-bitcoin-mining-asks-followers-to-help-dogecoin-de">had a &quot;potentially promising&quot; discussion</a> with &ldquo;North American Bitcoin miners&rdquo; about the&nbsp;environmental impact of cryptocurrency mining.
<blockquote class="twitter-tweet">Spoke with North American Bitcoin miners. They committed to publish current &amp; planned renewable usage &amp; to ask miners WW to do so. Potentially promising.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1396914548167233537?ref_src=twsrc%5Etfw">May 24, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>But Musk&#39;s participation&nbsp;in the Bitcoin mining movement was met with criticism by the cryptocurrency community.
In a Bloomberg interview, a prominent crypto expert and&nbsp;partner at Castle Island Ventures Nic Carter&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21313647/bitcoiners-intensely-skeptical-of-elon-musk-leading-bitcoin-mining-council">said</a> that &quot;Bitcoiners are still intensely skeptical of him, and they view him as conflicted frankly, given that his business partially involves the sale of offsets.&quot;
Read also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21531458/elon-musk-has-no-role-at-bitcoin-mining-council-say-founding-members">Elon Musk Has No Role At Bitcoin Mining Council, Say Founding Members</a>
What Else: In the tweet, Musk also confirmed that the company sold around 10% of its BTC holding just to show it &ldquo;could be liquidated easily&rdquo; and without &ldquo;moving the market.&rdquo;
Despite Musk&#39;s desire not to hurt the markets, Tesla&#39;s decision <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21096462/tesla-suspends-vehicle-purchases-via-bitcoin-over-environmental-concerns">to halt BTC payments</a> had a&nbsp;huge impact on&nbsp;the crypto prices. Bitcoin&nbsp;plummeted&nbsp;from $57,300 to $49,003 in a matter of hours.&nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

News

Entrepreneurship

Management

Markets

Tech

Media

General

$BTC

TSLA

Elon Musk Sets The Record Straight On When Tesla Will Accept Bitcoin Again

The U.S. Transportation Security Administration&nbsp;on Saturday said that it screened 2.03 million travelers at U.S. airport checkpoints on Friday.
For the first time since March 2020, the number of security screenings&nbsp;surpassed 2 million in a single day,&nbsp;<a href="https://apnews.com/article/coronavirus-pandemic-technology-health-lifestyle-travel-a2b3260a8633c2404dab44507b5de811">AP</a>&nbsp;reports.&nbsp;
According to TSA, the 2.03 million figure was 1.5 million more travelers than the same day in 2020, and the crowds were only 74% of the volume compared to the same day in 2019.
The lowest screening volume during the pandemic was on April 13, 2020, when just 87,534 individuals were screened at airport security checkpoints.
At that time CEO of&nbsp;Boeing Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) had predicted that at least one major U.S. airline would go bankrupt due to the pandemic-related downfall in the travel industry.&nbsp;
In April 2021,&nbsp;United Airlines Holdings Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ual#NASDAQ">UAL</a>) said that it added more than 480 daily flights to its U.S. schedule in June to meet summer travel demand.
Similarly,&nbsp;American Airlines Group Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aal#NASDAQ">AAL</a>) said in April it expects to fly more than 90% of its domestic seat capacity compared with summer 2019 and 80% of its international seat capacity compared with 2019, and it will operate more than 150 new routes this summer,&nbsp;<a href="https://www.reuters.com/business/autos-transportation/us-screens-163-million-people-airports-highest-since-march-2020-2021-05-03/" target="_blank">Reuters</a>&nbsp;reported.&nbsp;
More and more airlines are now seeing a surge in flight bookings with accelerated vaccine distribution and relaxed travel restrictions.&nbsp;
With a rebound in the sector, airlines are recalling employees from voluntary leave and planning to hire later this year.
The TSA is advising passengers to arrive at the airport with sufficient time to accommodate increased screening time as traveler volumes increase.&nbsp;
(Photo: United Airlines.)

Travel

US Travel Surges With 2 Million People Passing Through Airports, The Most Since March 2020

On June 1, Las Vegas lifted most of its <a href="https://www.lasvegasnevada.gov/News/Blog/Detail/corona-virus-update">COVID-19 restrictions</a> and its hotels and casinos have been welcoming back guests to dine, shop and gamble with few restrictions.
Wynn Resorts, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wynn#NASDAQ">WYNN</a>) which operates six properties in the U.S. and Macau -- most notably its flagship Wynn Las Vegas and Encore Las Vegas&mdash; was the <a href="https://www.ktnv.com/news/coronavirus/wynn-las-vegas-says-masks-no-longer-required-for-fully-vaccinated-guests">first resort</a> to update its policies and allow fully vaccinated guests to not wear masks at its Las Vegas hotels and casinos.
Las Vegas Sands Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lvs#NYSE">LVS</a>) followed and eased restrictions, including allowing fully vaccinated guests to not wear masks, at its Venetian and Palazzo at the Venetian resorts in Las Vegas.
As the vaccination effort continues to ramp up crowds of fully vaccinated travelers will continue to feel more at ease gathering at resorts and casinos and Wynn and Las Vegas Sands&rsquo; stocks look set to benefit.
The Wynn Chart: On May 24, Wynn broke up from a descending trendline (pink) that had been holding it down since March 16. After rising 7% between May 24 and June 2, the stock fell back down and retested the trendline as support and held above it. Wynn&rsquo;s stock has also continued to close above the ascending trendline (yellow) that has held as support since Jan.&nbsp;28.
On Friday, Wynn&rsquo;s stock printed a bullish green hammer candlestick, which indicates higher prices may come over the next few trading days. The long lower wick on the candle demonstrates that when the price dipped during Friday&rsquo;s session buyers came in.
Wynn is trading less than 1% below the eight-day and 21-day exponential moving averages (EMAs), which is slightly bearish, but bullish volume on Monday would help Wynn&rsquo;s stock to regain both EMAs as support fairly easily. The stock is trading well above the 200-day simple moving average (SMA), which indicates overall sentiment in Wynn is bullish.
<img alt="wynn_june_13.png" src="https://www.benzinga.com/files/u278075/wynn_june_13.png" style="height:394px; width:700px" />
Bulls want to see bullish volume come in and pop Wynn&rsquo;s stock up over the eight-day and 21-day EMAs to help push it up toward the $131 area. If the stock can regain those three levels as support, it has room to move up to $135.77.
Bears want to see the eight-day and 21-day EMAs continue to act as resistance and for the EMAs to push Wynn&rsquo;s stock down under support at $124.55. If Wynn lost that area of support, it could fall toward $120.
The Las Vegas Sands Chart: Las Vegas Sands has been trading in a downtrend since March 16, putting in fairly consistent lower highs and lower lows. In the downtrend, however, it has formed a bullish descending channel pattern. Las Vegas Sands, like Wynn, printed a bullish green hammer candlestick on Friday, indicating higher prices may be in the cards.
Although Las Vegas Sands doesn&#39;t look as bullish as Wynn in terms of the eight-day and 21-day EMAs and the 200-day SMA, the stock is trading within reach of each indicator. Bullish volume would allow Las Vegas Sands to easily recapture support of the 200-day SMA and the eight-day EMA, which would change both the long term and short-term sentiment bullish.
<img alt="lvs_june_13.png" src="https://www.benzinga.com/files/u278075/lvs_june_13.png" style="height:394px; width:700px" />
Bulls want to see bullish volume increase and for the stock to regain the 200-day SMA as support to push the stock up toward $56.71. If Las Vegas Sands&rsquo; stock was able to regain that level as support, and break up through the descending channel, it has room to move up toward $58.41.
Bears want to see the 200-day SMA act as resistance and push Las Vegas Sands&rsquo; stock down under support at $54.65. If the stock loses that level it could fall to $52.11
WYNN and LVS Price Action: Shares of Wynn closed up 0.79% Friday at $127.17 while Las Vegas Sands closed up 0.43% at $55.63.

Long Ideas

Short Ideas

Technicals

Trading Ideas

WYNN

Worth A Gamble? 2 Casino Stocks That Could See Upside

<ul>
<li>Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.</li>
<li>A SPAC, a REIT and some tech companies saw notable insider buying this past week.</li>
<li>Chief executive officers were among last week&#39;s insiders adding to their stakes as well.</li>
</ul>
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So <a href="https://www.benzinga.com/news/insider-trades">insider buying</a> can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets or the markets are near all-time highs.
Note that with the earnings reporting season officially over, insiders overall are no longer prohibited from buying or selling shares. Here are some of the most noteworthy insider purchases that were reported in the past week.
A former director of special purpose acquisition company ARYA Sciences Acquisition III Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arya#NASDAQ">ARYA</a>) returned to indirectly buy 5.50 million additional shares last week. At $10.00 per share, that cost that owner $55.00 million. Note that this SPAC is merging with Nautilus Biotechnology Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/naut#NASDAQ">NAUT</a>).
Two Enviva Partners LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eva#NYSE">EVA</a>) directors took advantage of a secondary offering to acquire almost 912,100 shares altogether of this producer of utility-grade wood pellets. At the offering price of $45.50 per share, these transactions added up to nearly $41.50 million. Shares were last seen at $49.10.
Asana Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/asan#NYSE">ASAN</a>) CEO Dustin Moskovitz purchased 910,000 shares throughout the week. He paid $37.10 to $46.14 apiece for those shares, which totaled more than $37.10 million. Note that another officer sold 30,000 shares of this San Francisco-based tech company during the week as well.
The purchase of more than 88,700 more PennyMac Financial Services Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfsi#NYSE">PFSI</a>) shares by a director (and frequent buyer) for $61.85 or so per share totaled more than $5.49 million. Note that the chief executive of this California-based mortgage company parted with 30,000 shares last week as well.
Safehold Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/safe#NYSE">SAFE</a>) saw a beneficial owner pick up almost 53,800 shares of this real estate investment trust at prices ranging from $73.00 to $76.01 apiece. These transactions totaled almost $4.00 million altogether. The stock popped more than 8% last week to close Friday at $76.91 a share.
Following a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21434009/5-lululemon-analysts-break-down-q1-beat-momentum-building-at-lulu">better than expected earnings report</a>, Lululemon Athletica Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) had a director purchase 4,800 shares at $330.00 apiece. This added up to more than $1.58 million. Note that another director sold about 310 shares, and the stock ended the week trading at $338.30 a share.
Biglari Holdings Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bh#NYSE">BH</a>) CEO Sardar Biglari stepped up to the buy window once again. The 1,400 or so class A shares that he indirectly acquired, at prices between $800.00 and $916.00, cost him around $1.22 million. Before these transactions, Biglari had purchased over 1,000 shares so far this month.
The CEO of cloud-based communications services provider 8x8, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eght#NYSE">EGHT</a>), David Sipes, scooped up 443,000 of the shares early in the past week. The share prices ranged from $23.44 to $23.50, and these purchases totaled almost $1.01 million. The timing looks fortunate, as the stock closed the week at $26.89 a share.
Opendoor Technologies Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) had a director add more than 59,300 shares to a stake in the past week. That totaled more than $1.00 million, at share prices averaging about $16.90. Note that an executive sold 75,000 shares of this online real estate services provider last week as well.
See also: <a href="https://www.benzinga.com/news/21/06/21464141/amc-has-seen-more-insiders-sell-in-past-week-than-the-entire-period-between-2017-and-2020-report">AMC Has Seen More Insiders Sell In Past Week Than The Entire Period Between 2017 And 2020: Report</a>
Note that some smaller amount of insider buying at Boyd Gaming Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/byd#NYSE">BYD</a>), Clearway Energy Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cwn#NYSE">CWN</a>), C3Ai Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>), Dollar Tree, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dltr#NASDAQ">DLTR</a>), FireEye Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feye#NASDAQ">FEYE</a>), Pacific Premier Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ppbi#NASDAQ">PPBI</a>), Roper Technologies Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rop#NYSE">ROP</a>) and Texas Pacific Land Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpl#NYSE">TPL</a>) was reported in the past week as well.

Small Cap

Insider Trades

ARYA

ASAN

DLTR

EGHT

FEYE

LULU

NAUT

OPEN

PFSI

PPBI

SAFE

Last Week's Notable Insider Buys: Lululemon Athletica, Opendoor Technologies And More

The Euro 2020 is set to begin June 11 with the Group Stage and run through July 11. The games will be aired on ESPN and EPSN+, both units of&nbsp;Walt Disney Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dis#NYSE">DIS</a>).
Ahead of the quadrennial soccer tournament featuring the top teams in Europe, Benzinga is providing group betting previews. Group F Betting Odds from Draftkings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). are:
<ul>
<li>France +143 to win Group F, -250 to finish in top two</li>
<li>Germany +175 to win Group F, -200 to finish in top two</li>
<li>Portugal +290 to win Group F, -165 to finish in top two</li>
<li>Hungary +4000 to win Group F, +850 to finish in top two</li>
</ul>
There are many betting options for soccer games which include betting on the winner, a tie, a team to win or tie, over/under, correct score, both teams to score and the winning margin.
For this betting preview, we will be looking at who is likely to win Group E and finish second as the top two teams will advance past the group stage.
The group of death is here with Group F featuring four teams from the top 40 rankings by FIFA, including three ranked in the top 12.
France (FIFA rank: 2) is favored to win the group but also offers decent betting odds at +143. The team went 8-1-1 in qualifying with Turkey being the team it couldn&rsquo;t get past with a loss and a draw. The team is the favorite to win the entire Euro 2020.
Germany (FIFA rank: 12) won its group going 7-0-1 in a competitive qualifying group with the Netherlands. The team posted a 3-2 win over the Netherlands and a 4-2 loss. The team had 30 goals scored and 7 goals allowed in qualifying.
If you take out the two matches against the Netherlands, Germany allowed only one goal and had five clean sheets in the other six matches.
Portugal (FIFA rank: 5) finished second to Ukraine in its qualifying group with a 5-2-1 record. The team led the group with a goal differential of 16 and saw 11 goals scored by Cristiano Ronaldo. The team had some questionable matches including a loss and draw with Ukraine and a 1-1 draw with Serbia.
The unfortunate team in the group of death is Hungary (FIFA rank: 37) which&nbsp;will not only find itself facing teams desperate for wins in the group but also looking to dominate goals scored and goal differentials for possible tie breaks.
The team finished 4-0-4 in qualifying, scoring only 8 goals in the matches.
Group F Picks: Bettors may want to consider staying away from&nbsp;group stage betting&nbsp;and place wagers on the top three teams for further on in the Euro.
The nice thing is that two teams will advance and a third could as well with the formatting of the tournament (top four third-place teams move on).
Since October, Germany has lost to North Macedonia and lost to Spain 6-0. This team could be seeking a chance to prove it is still a world power and could be the pick to win the group.
I think the group goes Germany, France, Portugal, but that could be a complete guess at this point.
(Image by&nbsp;<a href="https://pixabay.com/users/pixel2013-2364555/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3471402">S. Hermann &amp; F. Richter</a>&nbsp;from&nbsp;<a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=3471402">Pixabay</a>)

Sports

DKNG

Euro 2020 Group F Betting Preview And Picks

Boss Tweed, the notorious 19th-century New York City political chieftain, once remarked,&nbsp;&ldquo;The way to have power is to take it.&rdquo;
Tweed&rsquo;s philosophy appears to have survived well into the 21st century, at least according to Jan Eeckhout, author of the new book &ldquo;The Profit Paradox: How Thriving Firms Threaten the Future of Work.&rdquo;
In his book, Eeckhout details how a relatively small number of companies have created an off-kilter environment over the past four decades in which&nbsp;they have consolidated economic controls to a point where they can exist without fear of either competition or government regulation. As a result of this situation, workforce wages have mostly stagnated and prices on consumer and industrial goods are in constant ascension.
Eeckhout, who is the ICREA Research Professor at Pompeu Fabra University in Barcelona and previously taught at the University of Pennsylvania, University College London, Princeton University and New York University, spoke with Benzinga about &ldquo;The Profit Paradox&rdquo; and the state of global macroeconomy.
Benzinga: How did you come about with the thesis for your work?
JE: The thesis is based on facts, and we see two things. First of all, with the new fast technological change that&#39;s going on, we see that those highly productive firms &mdash;&nbsp;these very big innovators &mdash;&nbsp;have become very profitable, which is a good thing because innovation is a good thing. That&#39;s the driver of the economy, that&#39;s how we get progress and growth.
At the same time, this past ecological change has also led to a lopsidedness within the industries, because an Amazon&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) or a Facebook&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fb#NASDAQ">FB</a>) is so productive and is so much better than anyone else that they actually grab the entire market.
Still, couldn&rsquo;t an argument be made that these companies are giving the public what it wants?
JE: I&#39;m the first one who loves Amazon, because I get a lot of stuff at a low price and it&#39;s very convenient. But the reason why they can do it is because our central tenets of competition don&#39;t work.
What happens is that the first innovator in a market is the winner &mdash;&nbsp;it has competed heavily to get there. But once they&#39;re there, there&#39;s a huge barrier for other firms to come in to compete in that market.
Let me give you an example. In the &#39;90s,&nbsp;Yahoo tried&nbsp;to get into the online auction market but never got a hold because eBay (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) had 90% to 95% of the auction market.
But if you look at what happened in Japan, Yahoo Auctions was first and eBay has less than 5% of the market share &mdash;&nbsp;they can&#39;t get it. So, it&#39;s not that eBay is superior to Yahoo, it was that eBay was first.
See Also: <a href="https://www.youtube.com/watch?v=YOVpYSmmPwA">After Hours with Ryan Rozbiani: Will Inflation Crash The Market?</a>
But doesn&rsquo;t each generation bring a new wave of innovators creating different ways to change the economy?
JE: While the innovation was very valuable in the &#39;90s, 30 years on this innovation has stopped happening and the only thing that we see now is basically barriers to entry. The start-up rate is half what it was in the &#39;90s.
When people try to start up a new company, they face these huge giants and two things can happen with the giants: either they buy you, either at a price that&#39;s very low or in a killer acquisition where they buy and they just kill you off immediately, or they let you do what you do and they just copy your technology.
The COVID-19 pandemic created chaos on all economies around the world. Did this period of tumult change the landscape in any way for the better?
JE: From looking at the Dow Jones, the profitability of the largest firms has gone up even more &mdash;&nbsp;we know the Dow Jones is close to 35,000 and the growth since the pandemic has been enormous. This seems to indicate that what the pandemic has is to create innovation, and a lot of firms had to just be doing business in a different way. For example, you and I are talking over Zoom (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>), and many of our meetings would have been very different a year and a half ago.
But a lot of the smaller companies had to close down, either declaring bankruptcy or just simply leaving the market.
Overall, we see that large firms&rsquo; profitability had gone up even further than it was before the pandemic, and I think that&#39;s a sign that these firms have been beneficiaries of the pandemic.
What is the role of the government in addressing this situation?
JE: What I suggest in terms of government intervention &mdash;&nbsp;and it might sound like an oxymoron &mdash;&nbsp;but the government should ensure more competition. If a market has barriers to entry, anti-trust regulations should ensure more competition rather than less competition.
There&#39;s an important distinction to be made. There is a role for anti-trust legislation, but my view is they don&#39;t have to split up firms. There&#39;s no kind of gain in splitting up Amazon. The reason why Amazon is so efficient and cost-effective is because they&#39;re so large, so let&#39;s keep the size. But the government can do other things to induce competition.
Speaking of competition, how can the economy that you describe in your book compete against China?
JE: China is going through a transition from a planned economy to a market economy, and we see in the data that China is the one country where the degree of concentration is actually going down.
They still have a lot of state-owned enterprises which are massive, but these government companies are not very efficient and are now facing competition from many of the private companies in China.
As a result of that, there is a degree of competitiveness that&#39;s increasing because they&#39;re weeding out these massive state-owned enterprises. So, China is somewhat different from the rest of the world.
How does that work in terms of the competition? Ultimately, for the customer, it doesn&#39;t matter whether your company is Apple&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) or Alibaba (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>). I have an American phone in my pocket, and you probably drink a Belgian beer in the United States. If you read a book by Penguin, it&#39;s owned by a German company, and if you buy through Alibaba, it&#39;s a Chinese company.
But ultimately, it&#39;s the customer&#39;s location that matters because that is where the market power is,&nbsp;especially with the top 100 global firms, because that is exactly the kind of the issue of what&#39;s going on. It&#39;s a global phenomenon.
&ldquo;The Profit Paradox: How Thriving Firms Threaten the Future of Work,&rdquo; published by Princeton University Press.
(Photo of Jan Eekhout courtesy of ICREA.)

Economics

Exclusives

Interview

AAPL

AMZN

BABA

EBAY

EXCLUSIVE: Jan Eeckhout's 'The Profit Paradox' Details How Lack Of Competition Warps Economies

On Saturday, Barbora Krejcikova won just her second WTA women&rsquo;s singles title ever winning the 2021 Women&rsquo;s French Open.
Krejcikova entered the tournament with low odds to win the title, which could have turned in a nice profit for bettors.
What Happened: Krejcikova, who entered the French Open unseeded, beat 31st seeded Anastasia Pavlyuchenkova 6-1, 2-6 and 6-4 in three sets to win the 2021 French Open.
The match was Krejcikova&rsquo;s second singles tournament win and came in only the fifth major tournament the 25-year-old took part in.
Krejcikova is the third unseeded women&rsquo;s French Open winner since 2017, after a stretch of 1968 to 2016 that saw only seeded winners.
Related Link: <a href="https://www.benzinga.com/news/21/06/21369727/corporate-sponsors-back-naomi-osaka-on-her-french-open-withdrawal">Corporate Sponsors Back Naomi Osaka On Her French Open Withdrawal</a>
Betting Odds: Krejcikova was a slight favorite at -129 to beat Pavlyuchenkova (+108) entering Saturday&rsquo;s match, according to DraftKings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). The over/under hit the over (-113) of 21.5 games played.
Entering the 2021 French Open, Krejcikova had odds of +8000 (80/1) to win the title.
A $1,000 bet on Krejcikova to win the 2021 Women&rsquo;s French Open paid out a profit of $80,000 for anyone willing to place a bet on the unseeded tennis player from the Czech Republic.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/QkzmPG_tTFY" width="560"></iframe>

Here's The Huge Payout On A $1,000 Bet For Barbora Krejcikova Women's French Open Win

<a href="https://www.timesofisrael.com/liveblog-june-13-2021/" title="https://www.timesofisrael.com/liveblog-june-13-2021/">https://www.timesofisrael.com/liveblog-june-13-2021/</a>

Politics

iShares MSCI Israel Capped Investable Market Index Fund

Naftali Bennett of the Right-wing Yamina Party Was Sworn in Sunday as Israel's New Prime Minister, Replacing Benjamin Netanyahu After 12 Years in Power

<a href="https://twitter.com/elonmusk/status/1404132183254523905?s=20" title="https://twitter.com/elonmusk/status/1404132183254523905?s=20">https://twitter.com/elonmusk/status/1404132183254523905?s=20</a>

Movers & Shakers

BTBT

MARA

MSTR

RIOT

Elon Musk Tweeted: ...Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market.  When there's confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions.

<ul>
<li>ViacomCBS Inc&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viac#NASDAQ">VIAC</a>) Paramount Pictures film&nbsp;&ldquo;A Quiet Place 2&rdquo; has surpassed $100 million in U.S. ticket sales,&nbsp;<a href="https://variety.com/2021/film/news/a-quiet-place-2-box-office-milestone-pandemic-1234995367/" target="_blank">Variety</a>&nbsp;reports.&nbsp;&nbsp;</li>
<li>The film did $80 million at the international box office and $108 million at the domestic box office through the weekend.&nbsp;</li>
<li>&ldquo;A Quiet Place 2&rdquo; is the first pandemic-era film to play exclusively in theaters at&nbsp;AMC Entertainment Holdings Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>),&nbsp;Cinemark Holdings, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnk#NYSE">CNK</a>), and Regal cinemas.</li>
<li>The film debuted with a pandemic record of $48 million and made $58 million in its first five days of release. It was released over Memorial Day.&nbsp;</li>
<li>The first series of the film made $340 million globally and&nbsp;cost $17 million to produce. &ldquo;A Quiet Place 2&rdquo; was made at a budget of $61 million.</li>
<li>AT&amp;T Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)&nbsp;subsidiary Warner Bros. and Legendary Pictures Productions LLC&rsquo;s &ldquo;Godzilla vs. Kong&rdquo;&nbsp;is also reportedly heading toward&nbsp;the milestone in the next few days. The film&rsquo;s North American total was at $99.4 million.&nbsp;</li>
<li>The movie won&rsquo;t be available in the home via Paramount+ until 45 days after it first hit the big screen.</li>
<li>The last film to earn north of $100 million in North America was Paramount&rsquo;s &ldquo;Sonic the Hedgehog, &quot;&nbsp;released in February 2021.</li>
</ul>
Picture courtesy: Official Facebook page of the movie &ldquo;A Quiet Place 2&rdquo;

VIAC

'A Quiet Place 2' Breaks Pandemic-Era Box Office Records, Surpassing $100M

This article by Johnny Green was originally published on<a href="https://cannatechtoday.com/">&nbsp;Cannabis &amp; Tech Today</a>, and appears here with permission.
Historically, cannabis was portrayed as the scourge of humankind. Films like &lsquo;<a href="https://cannatechtoday.com/reefer-madness/">Reefer Madness</a>&rsquo;&nbsp;were coupled with other forms of propaganda and spread throughout the world.
That propaganda had one goal &ndash; to demonize cannabis users. Cannabis consumers were portrayed in horrific ways that weren&rsquo;t based in fact in an attempt to convince society that the &lsquo;harms&rsquo; of cannabis were significant and factual.
The fact of the matter is that cannabis is much safer than many other legal substances, including and especially alcohol.
One&nbsp;<a href="https://www.newsweek.com/cannabis-more-100-times-safer-alcohol-study-finds-309035">study</a>&nbsp;found that cannabis was 114 times safer than alcohol. A more recent study found that cannabis may actually be able to reduce alcohol cravings.
<h3>CBD and Alcohol Consumption Study</h3>
The&nbsp;<a href="https://cannatechtoday.com/canadian-medical-cannabis-patients-report-reductions-in-alcohol-use/">cannabis</a>&nbsp;plant is composed of dozens of cannabinoids, with THC and CBD being the two most popular cannabinoids.
CBD&rsquo;s popularity has exploded in recent years, and for good reason. CBD is associated with a number of wellness benefits, including a potential reduction in alcohol consumption.
Alcohol abuse is a global issue, with over 100 million people suffering from alcohol use disorder worldwide. Roughly 3 million people die annually across the globe due to alcohol use.
A team of researchers recently published results of a&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/33764086/">study</a>&nbsp;that explored the relationship between CBD use and alcohol use.
&ldquo;The present study lends preliminary support to the notion that plant-based CBD may be associated with decreased alcohol consumption among regular cannabis users and suggests that it may be feasible for regular cannabis users to switch to a higher CBD, lower THC content cannabis strain for the purposes of reducing their alcohol intake,&rdquo; the study&rsquo;s authors concluded.
<h3>Making the Safer Choice</h3>
If you feel that you consume too much alcohol and are having a hard time cutting back or eliminating alcohol from your life, you should definitely give CBD a try.
By virtually every measure CBD is safe, and as the study linked above demonstrates, it&rsquo;s effective for a lot of people when it comes to reducing alcohol consumption.
Unlike THC (and&nbsp;<a href="https://cannatechtoday.com/public_policy_alcohol_cannabis/">alcohol</a>), CBD is not associated with generating euphoric effects, which is obviously important for people that want to refrain from feeling intoxicated.
Thanks to cannabis reform victories in a laundry list of countries, CBD is now legal in many different forms and is widely available.
Read the original article on&nbsp;<a href="https://cannatechtoday.com/cbd-lower-alcohol-consumption/">Cannabis &amp; Tech Today</a>.
<a href="https://benzinga.com/cannabis/" rel="noopener noreferrer" target="_blank">Benzinga</a>&#39;s Related Links:&nbsp;
<ul>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/20/10/17746133/why-the-drinks-market-will-be-the-next-big-sector-in-cannabis-and-cbd&amp;sa=U&amp;ved=2ahUKEwjh0YOjsPfwAhVQErkGHeitBP4QFjACegQIABAC&amp;usg=AOvVaw0XQkjrPZ7Zcp0J0TD7zLFF" target="_blank">Why The Drinks Market Will Be The Next Big Sector In Cannabis</a></li>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/20/05/16057289/cbd-beer-the-bar-has-been-set-high-but-like-just-a-body-high&amp;sa=U&amp;ved=2ahUKEwjh0YOjsPfwAhVQErkGHeitBP4QFjAEegQIARAC&amp;usg=AOvVaw0NtmSPYK4CxRAz_2a1I7U1" target="_blank">CBD&nbsp;Beer: The Bar Has Been Set High, But Like, Just A Body High</a></li>
<li>M&aacute;s de&nbsp;<a href="https://elplanteo.com/author/cannabis-and-tech-today/">Cannabis &amp; Tech Today</a>&nbsp;en espa&ntilde;ol en El Planteo</li>
</ul>

Cannabis

Study Finds CBD Associated With Lower Alcohol Consumption

This article by Johnny Green was originally published on<a href="https://cannatechtoday.com/">&nbsp;Cannabis &amp; Tech Today</a>, and appears here with permission.
Currently, there are no fully legal adult-use cannabis countries in Europe, but Luxembourg is moving forward. The only two countries that have legalized cannabis for adult use are Uruguay and Canada.
With that being said, there are already countries in&nbsp;<a href="https://cannatechtoday.com/low-dose-cannabis-gains-in-popularity-in-europe/">Europe</a>&nbsp;that are quasi-legal, such as in Switzerland where low-THC cannabis is bought and sold legally.
In Italy, the Supreme Court ruled previously that home cultivation is legal, and while lawmakers are still trying to sort things out, there are now some legal protections in place for consumers.
Several countries are exploring legalization, and in some cases even launching limited pilot programs such as in the Netherlands, however, one country may be on the fastest path to full legalization in Europe.
<h3>Luxembourg Takes Another Step Forward</h3>
Luxembourg may not be the first country that people think of when it comes to the debate of which country will be the first to fully legalize in Europe.
After all, other countries like the Netherlands are typically much higher on the prediction scale given their longer history with cannabis and public policy.
However, Luxembourg might have more momentum than any other country in&nbsp;<a href="https://cannatechtoday.com/the-european-hemp-scene/">Europe</a>&nbsp;right now regarding legalization.
That was evident recently when lawmakers in Luxembourg&nbsp;<a href="https://twitter.com/ChambreLux/status/1395394796705964033">adopted a motion</a>&nbsp;calling for the development of legal cannabis regulations.
<h4>Will They Beat Other European Countries to Legalization?</h4>
Ultimately, only time will tell if Luxembourg becomes the first to legalize in&nbsp;<a href="https://cannatechtoday.com/report-uk-is-europes-largest-producer-exporter-of-legalized-cannabis/">Europe</a>.&nbsp;
Last summer officials in Luxembourg announced the desire to legalize cannabis for adult-use within two years.
The one year anniversary of that announcement is coming up soon, and with lawmakers calling for draft regulations, things are looking good.
Yet, as the push for legalization in Mexico has demonstrated in recent years, momentum can slow down very quickly.
Just as the push for legalization has experienced numerous setbacks in Mexico, the same could happen in Luxembourg if there is disagreement with provisions that eventually surface in the looming draft regulations.&nbsp;
Read the original article on&nbsp;<a href="https://cannatechtoday.com/luxembourg-closer-to-legalization/">Cannabis &amp; Tech Today</a>
<a href="https://benzinga.com/cannabis/" rel="noopener noreferrer" target="_blank">Benzinga</a>&#39;s Related Links:&nbsp;
<ul>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/markets/cannabis/21/04/20751935/why-2021-should-prove-the-year-of-federal-cannabis-legalization&amp;sa=U&amp;ved=2ahUKEwj5kaeIsvfwAhURDjQIHaMJC34QFjACegQIBBAC&amp;usg=AOvVaw0pPl9L_7Nyttzq_PTwycgl" target="_blank">Why 2021 Should Prove The Year Of Federal Cannabis&nbsp;Legalization</a></li>
<li><a dir="ltr" href="https://www.google.com/url?client=internal-element-cse&amp;cx=005794925877256802002:ckazbf3vrxs&amp;q=https://www.benzinga.com/topic/marijuana-legalization&amp;sa=U&amp;ved=2ahUKEwj5kaeIsvfwAhURDjQIHaMJC34QFjADegQIBxAB&amp;usg=AOvVaw29lH9n4HQQPYOkbb2ofhbD" target="_blank">marijuana&nbsp;legalization&nbsp;| Benzinga</a></li>
<li>M&aacute;s de&nbsp;<a href="https://elplanteo.com/author/cannabis-and-tech-today/">Cannabis &amp; Tech Today</a>&nbsp;en espa&ntilde;ol en El Planteo</li>
</ul>

Global

Luxembourg Moves One Step Closer To Cannabis Legalization

The graph displays total transaction consideration for U.S. and Canadian M&amp;A transactions since 2019.&nbsp;
<img src="https://lh4.googleusercontent.com/MCbp3fvZ2peViieQPsXaNc6SJnwXCKT2OnZT8I5CODscH3dNrH1r2jt8fFes9wOukHfXA20lbrarC5NbWu6CvMzmTCAWM4wdIcuFnEPDYQ42EaAF5qGH3O610ElSHYoxEGNtDuBE" style="height:429px; width:624px" />
<ul>
<li>
In the first half of 2019 the U.S and Canada were closely matched with approximately $2.1 billion of total consideration.&nbsp;&nbsp;
</li>
</ul>
<ul>
<li>
From the 2nd half of 2019 through 2020, Canadian M&amp;A ground to a near standstill while U.S. activity remained robust.
</li>
</ul>
<ul>
<li>
The U.S. dominance was supported by large transactions like Curaleaf&rsquo;s $949 million Select deal in Q1:20 and $830 million Grass Roots deal in Q3:20.
</li>
</ul>
<ul>
<li>
In Q1:21, activity in both countries spiked upward. U.S. activity benefitted from an increase in acquisitions of public companies including Liberty Health, Helix TCS, and Bluma Wellness. Canadian activity included a $353 million Canopy Growth divestiture of its ownership in Canopy Rivers.
</li>
</ul>
<ul>
<li>
Activity has accelerated in the second quarter with the recently completed $4.5B Tilray/Aphria megamerger in Canada and the $2.1B Trulieve/Harvest deal announced in the U.S.&nbsp;&nbsp;
</li>
</ul>
<ul>
<li>
Although consolidation among Canadian LPs in pursuit of positive cash flow is likely to continue, we expect the superior growth potential of the U.S. market to keep U.S. targets at the forefront of M&amp;A activity.
</li>
</ul>
The Viridian Capital Chart of the Week highlights key investment, valuation and M&amp;A trends taken from the Viridian Cannabis Deal Tracker.
The Viridian Cannabis Deal Tracker is a proprietary information service that monitors capital raise and M&amp;A activity in the legal cannabis and hemp industry. Each week the Tracker aggregates and analyzed all closed deals and segments each according to key metrics:
<ul>
<li>
Industry Sector (one of 12 sectors, from Cultivation to Brands)
</li>
<li>
Dollar value of the transaction
</li>
<li>
Region in which the deal occurred (country or U.S. state)
</li>
<li>
Status of the company announcing the transaction (Public vs. Private)
</li>
<li>
Deal structure (equity vs. debt)
</li>
<li>
Key deal terms (Pricing and Valuation)
</li>
</ul>
The <a href="https://viridianca.us1.list-manage.com/track/click?u=078ead34a8bbcfd77b0486326&amp;id=c89a19f9ee&amp;e=2699f9b787">Viridian Cannabis Deal Tracker</a> provides the market intelligence that cannabis companies, investors, and acquirers utilize to make informed decisions regarding capital allocation and M&amp;A strategy.
&nbsp;Since its inception in 2015, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,500 capital raises and 1,000 M&amp;A transactions totaling over $50 billion in aggregate value.
The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/como-comprar-dogecoin-doge-en-espana/">C&oacute;mo Comprar Dogecoin (DOGE) en Espa&ntilde;a</a></li>
<li><a href="https://elplanteo.com/acciones-de-marihuana/">C&oacute;mo Invertir en Acciones de Marihuana</a></li>
<li><a href="https://elplanteo.com/resena-etoro-2021/">eToro: Opiniones</a></li>
</ul>

Cannabis Industry Chart Of The Week: US Companies Pursue Growth Through M&A While Canada Consolidates

By Ed Donnelly, founder of AmourCBD
CBD, also known as cannabidiol, is the oil found in the stem of hemp plants which has the THC extracted to reach levels below 0.3%.&nbsp; CBD products have become an everyday essential and as travel begins to pick up, many people are unsure if they can bring their favorite CBD products with them.&nbsp; Here are a few things to keep in mind when bringing your CBD products along.
<ol>
<li>
Consider state laws
</li>
</ol>
Hemp&rsquo;s classification changed under the 2018 Farm Bill from being considered a Schedule I drug, meaning it is no longer considered a controlled substance, thus making consumption, production, and transportation across state lines legal 1. In order to even be considered hemp, products have to meet very strict requirements.&nbsp; For one, the THC percentage in the product cannot be higher than 0.3% otherwise it can be considered marijuana which is yet to be legalized on a federal level.&nbsp; When transporting hemp, the product has to be produced lawfully under the 2018 Farm Bill, and the USDA has to have issued approved regulations and procedures within that specific state.&nbsp; Each production plan was submitted individually by states&mdash;additional information pertaining to that can be found <a href="https://www.ams.usda.gov/rules-regulations/hemp/state-and-tribal-plan-review">here</a>.&nbsp;&nbsp;
<h3>TSA Compliant</h3>
While transporting marijuana across state lines is not allowed since it has not been legalized on a federal level, travelers can still bring most cannabis infused products with them, like CBD, as long as they contain under 0.3% THC 2.&nbsp; Like most hygienic products such as makeup and lotions, the TSA requires that any products brought in carry-on luggage do not exceed 3.4 oz and are stored in a resealable, clear 1 qt bag. Anything greater than 3.4 oz has to be stowed away in checked luggage. Additionally, CBD products do not need to be declared at the airport during domestic travel as they are federally legal in the United States.
<h3>Benefits of CBD for travel jitters</h3>
Why would travelers want to bring CBD along?&nbsp; Various studies have shown that CBD can be used to help alleviate symptoms associated with insomnia, anxiety, and some muscle pains 3.&nbsp; Whatever your fear may be, whether a fear of heights, flying in general, or uneasiness during turbulence, consuming CBD products can help significantly when conquering your flight.&nbsp; Not enough legroom or stiff muscles? CBD creams are your friend.&nbsp; If you want to combat jet lag or simply want to rest on a long flight, travelers can also use CBD in place of products like melatonin.
<h3>International Travel Guidelines</h3>
When traveling internationally, CBD regulations can become a bit less straightforward. While it is legal to travel with CBD products containing less than 0.3% THC domestically in the United States, other countries have different laws regarding CBD use. Before bringing CBD products along for international travel, check on the regulations of the country you are traveling to in order to ensure you are abiding by that country&rsquo;s laws. If you are unsure, professionals suggest leaving CBD products at home since many countries have stricter CBD-related drug laws than the United States 4.
<h3>Check for THC in CBD Products</h3>
Be sure to double check the ingredients of your CBD products before travel. As previously stated, CBD products containing less than 0.3% THC are federally legal, but CBD products containing higher doses of THC can vary in legality by state. Especially when traveling to or from a state where marijuana is legal, make sure to check your CBD products for their THC levels.&nbsp;
Keeping rules and regulations in mind when traveling with your CBD must-haves can help ensure a smooth and relaxing trip, especially during a time we need it most.
Ed Donnelly Bio:
Ed Donnelly is a CBD expert and founder of AmourCBD.&nbsp; With over 30 years of experience working as a Burn Center Nurse in New York and then moving on to assume executive roles in medical technology sales companies, Donnelly entered a new chapter in life when he founded AmourCBD.&nbsp; Combining his experience as a businessman and medical professional, Ed is driven to bring high quality, medical grade products to the CBD market.&nbsp;
Encuentra nuestro contenido en Espa&ntilde;ol en El Planteo:
<ul>
<li><a href="https://elplanteo.com/avion-marihuana/">Aviones, Cannabis y Leyes: &iquest;Podemos Viajar con Marihuana?</a></li>
<li><a href="https://elplanteo.com/viajar-en-pareja-como-los-psicodelicos-pueden-fortalecer-tu-relacion/">Viajar en Pareja: C&oacute;mo los Psicod&eacute;licos Pueden Fortalecer tu Relaci&oacute;n</a></li>
<li>Photo by <a href="https://unsplash.com/@darya_tryfanava?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Darya Tryfanava</a> on <a href="https://unsplash.com/s/photos/plane?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a></li>
</ul>

What To Know Before Traveling With CBD

Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.
The biggest biotech news of the week came in the form of <a href="https://www.benzinga.com/general/biotech/21/06/21455132/biogen-gets-fda-nod-for-controversial-alzheimers-drug-first-treatment-approval-for-the-disease-in"> approval </a> for Biogen Inc.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) Alzheimer&#39;s drug Aduhelm. The approval polarized the scientific community. The stock, which at one point tacked on about 64% on the day of the approval, ended the week up about 40%.
Alexion Pharmaceuticals, Inc.&#39;s(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alxn#NASDAQ">ALXN</a>) Ultomiris received label expansion to treat paroxysmal nocturnal hemoglobinuria in children and adolescents.
Among other approvals that came through during the week were label expansion for Vertex Pharmaceuticals Incorporated&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) triple combo cystic fibrosis drug Trikafta and Pfizer Inc.&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) 20-valent pneumococcal conjugate vaccine.
Vertex, however, had a mixed week, as it <a href="https://www.benzinga.com/general/biotech/21/06/21525331/despite-hitting-mid-stage-trial-endpoint-goal-vertex-strikes-out-rare-lung-disease-candidate-stoc"> announced</a>&nbsp;the shelving of a mid-stage study of a drug for a&nbsp;rare, inherited lung disease.
The week also saw a slew of presentations at multiple scientific meetings. The ASCO 2021 that kickstarted on June 4 ended in the first half of the week, and the European Hematology Association Congress commenced in the later half of the week.
Danish biotech Orphazyme A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orph#NASDAQ">ORPH</a>) and Galecto, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glto#NASDAQ">GLTO</a>) had a volatile ride this week amid a lack of any news specific to the companies.
Here are the key catalysts for the unfolding week:
<h3>Health Care Conferences</h3>
<ul>
<li>BIO Digital 2021: June 14-18</li>
<li>The BofA Securities 2021 Napa Biopharma Virtual Conference: June 14-16</li>
<li>Citi European Healthcare Day: June 15-16</li>
<li>The JMP Securities Life Sciences Conference: June 16-17</li>
<li>J.P. Morgan European Healthcare Conference: June 17</li>
<li>Alliance Global Partners Healthcare Symposium Virtual: June 17</li>
<li>H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference: June 17</li>
</ul>
Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21351378/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-limi"> Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates </a>
<h3>PDUFA Dates</h3>
The FDA is likely to announce by Tuesday, June 15&nbsp;its decision on Takeda Pharmaceutical Company Limited&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tak#NYSE">TAK</a>) new drug application for TAK-721 as a treatment option for eosinophilic esophagitis.
Blueprint Medicines Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpmc#NASDAQ">BPMC</a>) has a decision date of Wednesday, June 16 for its supplemental NDA for Ayvakit as a treatment option for advanced systemic mastocytosis.
The FDA is scheduled to rule on Orphazyme&#39;s NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, a rare, progressive, neurodegenerative disease.
The PDUFA date has been set for Thursday, June 17. Arimocolmol was developed by CytRx Corporation (OTC: <a class="ticker" href="https://www.benzinga.com/stock/cytr#OTC">CYTR</a>) and has been licensed to Orphazyme.
Eton Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eton#NASDAQ">ETON</a>) has a decision-by date of Friday, June 18&nbsp;for its NDA for its ready-to-use ephedrine injection to treat low blood pressure.
<h3>Earnings</h3>
Centogene N.V.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntg#NASDAQ">CNTG</a>) (Wednesday)
<h3>IPOs</h3>
IPO Pricing &amp; Listing 
Atai Life Sciences B.V., a clinical-stage biopharma developing treatments for mental health disorders, has commenced a proposed underwritten initial public offering of 14.286 million shares of its common shares. All common shares to be sold in the proposed offering will be sold by Atai. 
The IPO price is expected to be between $13 and $15 per common share. The German pyschedelics company has applied to list its common shares on the Nasdaq under the ticker symbol &quot;ATAI.&quot;
South San Francisco, California-based Lyell Immunopharma, Inc. has filed for offering 25 million shares of its common stock in an IPO. The oncology-focused company that uses T cells to cure solid tumors, expects to price the offering between $16 and $18. It has applied to list its shares on the Nasdaq under the ticker symbol &quot;LYEL.&quot;
Swiss biopharma Molecular Partners AG proposes to offer 3 million ADSs in an IPO, with each ADS representing the right to receive one common share. The company has given an indicative price of $27.14 per ADS, going by the 24.40 Swiss-franc-per-share price at which its Swiss exchange listed shares closed June 8. The biopharma that focuses on infectious disease, oncology and ophthalmology, has applied to list its ADSs on the Nasdaq under the symbol &quot;MOLN.&quot;
Unicycive, a Los Altos, California-based biopharma that focuses on treatment of kidney diseases, has filed to offer $2.635 million shares at an estimated price range of $8.50-$1.50. The company has applied for listing its shares on the Nasdaq under the ticker symbol &quot;UNCY.&quot;
Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21516069/with-aduhelm-approval-behind-biogen-5-catalysts-for-investors-to-watch"> With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch </a>

Biotech

Earnings

Penny Stocks

Health Care

Previews

IPOs

ALXN

BIIB

BPMC

CNTG

CYTR

ETON

GLTO

ORPH

VRTX

The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs

Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spfr#NYSE">SPFR</a>), the blank-check firm that is set to take 3D printing company Velo3D public.
Shares of the company closed down 0.3% to $10 on Friday.&nbsp;
The Ark Autonomous Technology &amp; Robotics ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkq#BATS">ARKQ</a>) bought shares of Jaws Spitfire. Besides ARKQ, the Ark Space Exploration &amp; Innovation ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkx#BATS">ARKX</a>) also holds shares of the blank-check firm, or&nbsp;special purpose acquisition vehicle.
Velo3D is a 3D printer supplier for SpaceX, the space exploration company led by Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk. It expects the deal with Jaws Spitfire to close in the second half of the year and list under the &quot;VLD&quot; ticker on the New York Stock Exchange.
The company, backed by tennis player Serena Williams, was founded by Miami-based investment firm Starwood Capital Group&rsquo;s Barry Sternlicht, which has about $80 billion worth of assets under management.
On a consolidated basis, ARKQ and ARKX together held 3.42 million shares, worth $34.32 million, in Jaws Spitfire.&nbsp;
See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/21/05/21311511/cathie-wood-loads-up-another-292k-in-spacex-partner-velo3ds-spac?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga%2Fbest-of-benzinga+%28The+Best+of+Benzinga%29&amp;utm_content=Google+Feedfetcher" style="text-decoration:none">Cathie Wood Loads Up Another $292K In SpaceX Partner Velo3D&#39;s SPAC</a>
The investment firm&#39;s&nbsp;3D Printing ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/prnt#BATS">PRNT</a>) is dedicated to the 3D printing industry. PRNT has grown about 21.7% so far this year and has 3D Systems Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) as its top holdings among a total of 56 stocks.
The New York-based investment firm also bought 154,453 shares, worth about $29.8 million, in biotech company Vertex Pharmaceuticals Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>) on the dip.
Shares of Vertex Pharmaceuticals closed about 11% lower to $193.02 on Friday.&nbsp;
Barclays on Friday <a href="https://www.benzinga.com/analyst-ratings/price-target/21/06/21526917/10-biggest-price-target-changes-for-friday">lowered</a>&nbsp;its&nbsp;Vertex Pharmaceuticals&nbsp;price target from $302 to $285.
Some of the other key Ark Invest sells on Friday included Guardant Health Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gh#NASDAQ">GH</a>) and buys included 908 Devices Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mass#NASDAQ">MASS</a>).&nbsp;
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/NUehKZBLBCQ" width="560"></iframe>

Sector ETFs

ETFs

ARKQ

ARKX

MASS

PRNT

SPFR

Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip

<ul>
<li>Thrasio, a start-up company that rolls up&nbsp;Amazon.com, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) marketplace brands, is in talks to go public through a merger with the blank check company&nbsp;Churchill Capital V Corp&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccv#NYSE">CCV</a>),&nbsp;<a href="https://www.bloomberg.com/news/articles/2021-06-11/thrasio-is-said-in-talks-to-go-public-via-michael-klein-spac?sref=TBDibEcD">Bloomberg</a>&nbsp;reported,&nbsp;citing people with knowledge of the matter.</li>
<li>No deal has been finalized yet, and the merger could fall apart, the report said.&nbsp;</li>
<li>Thrasio could be valued at $2 billion in the merger. According to people familiar with the subject, the valuation may reach up to $10 billion, the Friday report said.&nbsp;</li>
<li>Former Citigroup Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) rainmaker Michael Klein set&nbsp;up Churchill Capital V.&nbsp;</li>
<li>In January, Thrasio raised $500 million via&nbsp;JPMorgan Chase &amp; Co.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>),&nbsp;Goldman Sachs Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>)&nbsp;and the asset management arm of&nbsp;Royal Bank of Canada&nbsp;(TSE: RY).</li>
<li>The company has also raised $260 million in C funding led by Advent International.</li>
<li>Thrasio aims to capitalize on Amazon&rsquo;s e-commerce dominance by acquiring new sellers on its third-party marketplace.</li>
<li>In December 2020, Churchill Capital V raised $500 million in its initial public offering.</li>
</ul>

Emerging Market ETFs

Startups

Thrasio In Talks To Merge With SPAC Churchill Capital V: Report

-Reuters
<a href="https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/" title="https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/">https://www.reuters.com/business/retail-consumer/exclusive-washington-prime-file-bankruptcy-soon-this-week-sources-2021-06-13/</a>

Rumors

Legal

Washington Prime Group to File Bankruptcy as Soon as this Week

Futures

Commodities

Asset Sales

RDS.A

RDS.B

Reuters Reports Royal Dutch Shell Preparing Potential Sale of Its U.S. Permian Basin Assets Which are Expected to Fetch $10B+

LeBron James is switching his jersey next season from number 23 to number 6. Here&rsquo;s a look at how James has performed stat-wise and sports-betting-wise for both jersey numbers.
What Happened: LeBron James spent the last three seasons with the Los Angeles Lakers and 11 prior seasons with the Cleveland Cavaliers with the jersey number 23. James will be <a href="https://www.benzinga.com/news/21/06/21481507/nikes-new-lebron-19-shoes-to-debut-in-space-jam-2">wearing </a>jersey #6 for the Tune Squad in &ldquo;Space Jam: A New Legacy,&rdquo; a new film from AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>).
In his four seasons with the Miami Heat, James wore jersey number 6. This is how James has performed stat-wise based on his teams:
<ul>
<li>Cleveland Cavaliers: 27.2 points, 7.3 rebounds, 7.3 assists</li>
<li>Miami Heat: 26.9 points, 7.6 rebounds, 6.7 assists</li>
<li>Los Angeles Lakers: 25.9 points, 8.0 rebounds, 8.9 assists</li>
<li>Career: 27.0 points, 7.4 rebounds, 7.4 assists</li>
</ul>
In his four seasons with the Heat and jersey #6, James posted these stat lines:
<ul>
<li>2010-2011: 26.7 points, 7.5 rebounds, 7.0 assists</li>
<li>2011-2012: 27.1 points, 7.9 rebounds, 7.2 assists</li>
<li>2012-2013: 26.8 points, 8.0 rebounds, 7.3 assists</li>
<li>2013-2014: 27.1 points, 6.9 rebounds, 6.3 assists</li>
</ul>
Here&rsquo;s how James has performed for bettors with both jersey numbers, according to <a href="https://twitter.com/ActionNetworkHQ/status/1402990684932505602">Action Network</a>.
<ul>
<li>#6 Straight Up: 274-107, 71.9%</li>
<li>#6 Against the Spread: 196-182-3, 51.9%</li>
<li>#23 Straight Up: 770-424, 64.5%</li>
<li>#23 Against the Spread: 597-577-20, 50.9%</li>
</ul>
The results above show that James performs better for bettors on average when he is wearing jersey number 6.
Related Link: <a href="https://www.benzinga.com/general/sports/21/06/21438793/nba-finals-wont-feature-one-of-these-7-players-for-first-time-since-1990">NBA Finals Won&rsquo;t Feature One Of These 7 Players For First Time Since 1990</a>
Disappointing Season?: Heading into 2021, the Lakers were the favorite to win the NBA Championship with odds of +270 from DraftKings Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dkng#NASDAQ">DKNG</a>). Heading into the NBA Playoffs, the Lakers <a href="https://dknation.draftkings.com/2021/5/17/22436125/nba-playoffs-2021-championship-odds-to-win-nets-lakers-bucks-sleepers-jazz-suns-favorites-warriors">had </a>the second-best odds to win&nbsp;at odds of +400 behind the Brooklyn Nets at +250.
For the <a href="https://www.benzinga.com/general/sports/21/06/21415766/will-lebron-lose-his-perfect-14-0-record-in-the-first-round-suns-lakers-game-6-betting-preview-pic">first time</a> in his NBA career, James was knocked out in the first round, after going 14-0 in his prior NBA Playoffs history.
James <a href="https://www.nba.com/news/nikola-jokic-wins-2020-21-kia-nba-most-valuable-player-award">had </a>odds to win the NBA MVP of +700 to start the season, raking slightly behind favorites Giannis Antetokounmpo and Luka Doncic at +600. James had his odds drop down to +175 later on in the season.
James finished&nbsp;13th in the NBA MVP voting by 100 panelists and a vote from the fans. James finished with one fifth-place vote, good for one weighted point overall. Nikola Jokic <a href="https://www.benzinga.com/general/sports/21/06/21492063/heres-how-much-a-preseason-1-000-bet-on-nikola-jokic-to-win-nba-mvp-paid-out">won </a>the MVP with 91 first-place votes and 971 total weighted points.
What&rsquo;s Next: The Lakers will likely be among the top favorites for the 2021-2022 NBA season. James could be determined to have a bounce-back season after getting knocked out early in the NBA Playoffs and getting only one vote in the MVP race.
Photo by&nbsp;<a href="https://unsplash.com/@chichi1813?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Chichi Onyekanne</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/lebron?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

LeBron James Switching Jersey Number From 23 To 6: Here's Which Jersey James Helps Bettors In More

11 IPOs have been scheduled this week, aiming to raise more than $2.7 billion, led by dating app Bumble&#39;s billion-dollar offering.

<h4>Bumble</h4>

Bumble (NASDAQ:<a class="ticker" href="/stock/BMBL#NASDAQ">BMBL</a>) operates the Bumble and Badoo apps, the world&#39;s second and fourth highest grossing dating apps. It initially planned to raise $1.0 billion at a $5.8 billion market cap. On Monday, it raised the size of its IPO offering to 45 million shares, now expecting to raise $1.8 billion and targeting a valuation of $7 billion. Operating in a competitive market with low barriers to entry, Bumble was profitable on an EBITDA basis in the first three quarters of 2020, with growth accelerating in the most recent quarter. The filing reveals its average monthly userbase has 42 million, out of which 2.4 million are paying users.

<h4>Signify Health</h4>

A value-based billing platform for in-home and bundled health services, Signify Health (NASDAQ:<a class="ticker" href="/stock/SGFY#NASDAQ">SGFY</a>), plans to raise 423 million at a $4.1 billion market cap. The Norway-based company has demonstrated growth and was profitable on an EBIT basis during the first nine months of 2020.

<h4>loanDepot</h4>

After delaying its IPO last week, the nonbank lender loanDepot (NASDAQ:<a class="ticker" href="/stock/LDI#NASDAQ">LDI</a>) now plans to raise $300 million at a $6.2 billion market cap. The company offers loan origination and servicing, while focusing on mortgage and unsecured personal loans. Although it is fast growing and profitable, it operates in a highly cyclical industry and if we are to judge by recent mortgage lenders that went public, there probably won&#39;t be much of a reception.

<h4>Cloopen Group Holding</h4>

China&#39;s largest multi-capability cloud-based communications solution provider by 2019 revenue, Cloopen Group Holding (NASDAQ:<a class="ticker" href="/stock/RAAS#NASDAQ">RAAS</a>) plans to raise $280 million at a $2.1 billion market cap. Unprofitable with decelerating growth during the first nine months of 2020, Cloopen Group had an active customer base of over 12,000 enterprises as of the end of September 2020.

<h4>Viant Technology</h4>

Advertising software maker Viant Technology (NASDAQ:<a class="ticker" href="/stock/DSP#NASDAQ">DSP</a>) initially planned to raise $150 million at a $1.3 billion market cap. The Irvine, CA-based company raised the deal size by 30% and it now plans to raise $196 million. The company&#39;s software brings programmatic advertising to life by enabing the electronification of the advertising buying process. While the company&#39;s active customers declined during the first three quarters of 2020, average revenue ex-TAC per active customer rose 23% YoY.

<h4>Apria</h4>

A provider of integrated home healthcare equipment and services, Apria (NASDAQ:<a class="ticker" href="/stock/APR#NASDAQ">APR</a>) plans to raise $150 million at a $756 million market cap. The company is profitable but it is growing slowly, having served almost 2 million patients, with 2.4 million deliveries, and over 744,000 clinician interactions with patients in 2019.

<h4>Adagene</h4>

Chinese cancer biotech Adagene (NASDAQ:<a class="ticker" href="/stock/ADAG#NASDAQ">ADAG</a>) plans to raise $132 million at an $831 million market cap. Its most advanced candidate ADG106 is undergoing Phase 1 trials both in the US and China. The drug that is designed to target a unique antibody that is different from any anti-CD137 antibodies currently in development.

<h4>Bioventus</h4>

After four years, orthobiologic therapy developer Bioventus (NASDAQ:<a class="ticker" href="/stock/BVS#NASDAQ">BVS</a>) is hoping that second time&#39;s the charm as it plans to raise $125 million at a $922 million market cap. The company&#39;s competitive advantage lies in developing and commercializing clinically differentiated, cost efficient, and minimally invasive treatments that aim to boost the body&#39;s natural healing capability. It is profitable despite revenue falling due to COVID-related declines in volume during the first three quarters of 2020.

<h4>REIT AFC Gamma</h4>

Cannabis finance REIT AFC Gamma (NASDAQ:<a class="ticker" href="/stock/AFCG#NASDAQ">AFCG</a>) plans to raise $100 million at a $214 million market cap. A West Palm Beach, Florida-based company was founded in July 2020 and it offers loans to established cannabis companies in states where marijuana is legal for medical or recreational use.

<h4>Longeveron</h4>

Cell therapy biotech Longeveron (NASDAQ:<a class="ticker" href="/stock/LGVN#NASDAQ">LGVN</a>) plans to raise $25 million at a $194 million market cap. Longeveron is developing cellular therapies for specific aging and life-threatening conditions. It is currently sponsoring Phase 1 and 2 trials in five indications of its lead product.

<h4>Biophytis</h4>

French-listed biotech Biophytis (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) plans to raise $20 million at a $195 million market cap. Its lead candidate is an orally administered small molecule in development for the treatment of neuromuscular diseases and is currently in a Phase 2 trial for sarcopenia, with top-line results expected in the 2Q21, along with an ongoing Phase 2/3 study for SARS-CoV-2 pneumonia.

<h4>The IPO market is still hot</h4>

By the looks of it, the IPO market is not losing momentum and we are in for another diverse IPO week, including dating, cannabis, communication with biotech and healthcare leading the way.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full <a href="https://iamnewswire.com/disclaimer-disclosure/">disclosure</a> . IAM Newswire does not hold any position in the mentioned companies. Press Releases &ndash; If you are looking for full Press release distribution contact: <a href="mailto:press@iamnewswire.com">press@iamnewswire.com</a> Contributors &ndash; IAM Newswire accepts pitches. If you&#39;re interested in becoming an IAM journalist contact: <a href="mailto:contributors@iamnewswire.com">contributors@iamnewswire.com</a>

The post <a href="https://iamnewswire.com/2021/02/09/the-ipo-week-ahead/" rel="nofollow">The IPO Week Ahead</a> appeared first on <a href="https://iamnewswire.com" rel="nofollow">IAM Newswire</a>.

The IPO Week Ahead

Biophytis Shares Open For Trade At $18.50; IPO Priced At $16.75/Share

52-Week Highs:

<ul>
	<li>Gores Holdings VI (GHVI)</li>
	<li>Turquoise Hill Resources (TRQ)</li>
	<li>SOC Telemed (TLMD)</li>
	<li>Churchill Capital (CCIV)</li>
	<li>Wix.com (WIX)</li>
	<li>Fortinet (FTNT)</li>
	<li>Helix Acquisition (HLXA)</li>
	<li>Robert Half International (RHI)</li>
	<li>JPMorgan Chase (JPM)</li>
	<li>Raven Industries (RAVN)</li>
	<li>Viomi Technology (VIOT)</li>
	<li>Focus Financial Partners (FOCS)</li>
	<li>ChromaDex (CDXC)</li>
	<li>Motus GI (MOTS)</li>
	<li>Titan Pharmaceuticals (TTNP)</li>
	<li>Camber Energy (CEI)</li>
	<li>Container Store Group (TCS)</li>
	<li>Allegiant Travel (ALGT)</li>
	<li>HighCape Capital Acquisition (CAPA)</li>
	<li>Milestone Scientific (MLSS)</li>
	<li>IDEXX Laboratories (IDXX)</li>
	<li>Albany International (AIN)</li>
	<li>NantKwest (NK)</li>
	<li>Amerco (UHAL)</li>
	<li>Teledyne Technologies (TDY)</li>
	<li>New Frontier Health (NFH)</li>
	<li>Mereo BioPharma Group (MREO)</li>
	<li>North American (NOA)</li>
	<li>Shutterstock (SSTK)</li>
	<li>Bloomin Brands (BLMN)</li>
	<li>Lion Group Holding (LGHL)</li>
	<li>Lantronix (LTRX)</li>
	<li>Expedia Group (EXPE)</li>
	<li>Takung Art (TKAT)</li>
	<li>UniFirst (UNF)</li>
	<li>Tractor Supply (TSCO)</li>
	<li>White Mountain Insurance (WTM)</li>
	<li>Johnson Outdoors (JOUT)</li>
	<li>TripAdvisor (TRIP)</li>
	<li>Transcat (TRNS)</li>
	<li>MediaAlpha (MAX)</li>
	<li>Holicity (HOL)</li>
	<li>Rafael Holdings (RFL)</li>
	<li>Onconova Therapeutics (ONTX)</li>
	<li>Taitron Components (TAIT)</li>
	<li>Par Technology (PAR)</li>
	<li>Atlassian Corporation (TEAM)</li>
	<li>Coupa Software (COUP)</li>
	<li>Fluent (FLNT)</li>
</ul>

<div>52-Week Lows:</div>

<ul>
	<li>Golden Nugget Online (GNOG)</li>
	<li>United Wholesale Mortgage (UWMC)</li>
	<li>Galapagos (GLPG)</li>
	<li>Advent Technologies (ADN)</li>
	<li>iSun (ISUN)</li>
	<li>Romeo Power (RMO)</li>
	<li>Clover Health Investments (CLOV)</li>
	<li>Ark Global Acquisition (ARKIU)</li>
	<li>American Electric Power (AEPPL)</li>
	<li>McCormick &amp; Co (MKC)</li>
	<li>uniQure (QURE)</li>
	<li>Lazard Growth Acquisition (LGACU)</li>
	<li>ON24 (ONTF)</li>
	<li>Virpax Pharmaceuticals (VRPX)</li>
	<li>Petco Health and Wellness (WOOF)</li>
	<li>Avidity Biosciences (RNA)</li>
	<li>Brookfield Renewable (BEPC)</li>
	<li>Sana Biotechnology (SANA)</li>
	<li>Vallon Pharmaceuticals (VLON)</li>
	<li>Biophytis (BPTS)</li>
	<li>Global Internet of People (SDH)</li>
	<li>Washington Federal (WAFDP)</li>
	<li>Pathfinder Acquisition (PFDRU)</li>
	<li>RLX Technology (RLX)</li>
	<li>Pharming (PHAR)</li>
	<li>Baosheng Media (BAOS)</li>
	<li>GTT Communications (GTT)</li>
</ul>

Movers

Stocks Making New 52-Week Highs/Lows For Thursday, Feb. 18, 2021 (Via Benzinga Pro's Signals Tool)

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs Feb. 19)

<ul>
	<li>Angion Biomedica Corp (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>)</li>
	<li>Antares Pharma Inc (NASDAQ:<a class="ticker" href="/stock/ATRS#NASDAQ">ATRS</a>)</li>
	<li>Applied Molecular Transport Inc. (NASDAQ:<a class="ticker" href="/stock/AMTI#NASDAQ">AMTI</a>)</li>
	<li>Avanos Medical Inc (NYSE:<a class="ticker" href="/stock/AVNS#NYSE">AVNS</a>) (reacted to its fourth-quarter results)</li>
	<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/CLDX#NASDAQ">CLDX</a>)</li>
	<li>Cellular Biomedicine Group Inc (NASDAQ:<a class="ticker" href="/stock/CBMG#NASDAQ">CBMG</a>)</li>
	<li>Cleveland BioLabs, Inc. (NASDAQ:<a class="ticker" href="/stock/CBLI#NASDAQ">CBLI</a>)</li>
	<li>Endo International PLC (NASDAQ:<a class="ticker" href="/stock/ENDP#NASDAQ">ENDP</a>)</li>
	<li>Immunome Inc (NASDAQ:<a class="ticker" href="/stock/IMNM#NASDAQ">IMNM</a>) (<a href=" https://www.benzinga.com/general/biotech/21/02/19725615/immunome-shares-spike-150-higher-on-coronavirus-antibody-discovery"> reacted </a> to discovery of antibodies against coronavirus variants)</li>
	<li>Mereo BioPharma Group plc &ndash; ADR (NASDAQ:<a class="ticker" href="/stock/MREO#NASDAQ">MREO</a>)</li>
	<li>Nantkwest Inc (NASDAQ:<a class="ticker" href="/stock/NK#NASDAQ">NK</a>)</li>
	<li>Onconova Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/ONTX#NASDAQ">ONTX</a>)</li>
	<li>Processa Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/PCSA#NASDAQ">PCSA</a>)</li>
	<li>Prothena Corporation PLC (NASDAQ:<a class="ticker" href="/stock/PRTA#NASDAQ">PRTA</a>)</li>
	<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RIGL#NASDAQ">RIGL</a>)(<a href=" https://www.benzinga.com/general/biotech/21/02/19727533/lilly-strikes-licensing-deal-with-rigel-in-push-toward-neurological-immunological-therapies"> announced a </a> licensing and collaboration deal with Eli Lilly And Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>))</li>
	<li>Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ:<a class="ticker" href="/stock/SLN#NASDAQ">SLN</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows Feb. 19)

<ul>
	<li>Avidity Biosciences Inc (NASDAQ:<a class="ticker" href="/stock/RNA#NASDAQ">RNA</a>)</li>
	<li>Biophytis SA ADR (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) (received regulatory nod in France and Belgium for expansion of patient recruitment for Part 2 of the Phase 2/3 COVID-19 study)</li>
	<li>Bioventus Class A Ord Shs (Proposed) (NASDAQ:<a class="ticker" href="/stock/BVS#NASDAQ">BVS</a>)</li>
	<li>Pharming Group N V ADS each representing 10 Ord Shs (NASDAQ:<a class="ticker" href="/stock/PHAR#NASDAQ">PHAR</a>)</li>
	<li>Sana Biotechnology Inc (NASDAQ:<a class="ticker" href="/stock/SANA#NASDAQ">SANA</a>)</li>
	<li>Uniqure NV (NASDAQ:<a class="ticker" href="/stock/QURE#NASDAQ">QURE</a>)</li>
	<li>Vallon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/VLON#NASDAQ">VLON</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Novavax Strikes $1B-dose Vaccine Supply Deal With Gavi</h3>

Novavax, Inc. (NASDAQ:<a class="ticker" href="/stock/NVAX#NASDAQ">NVAX</a>) announced a memorandum of understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373, the company&#39;s recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility.

COVAX is a vaccine partnership co-led by the CEPI, Gavi and the WHO, which are working along with developed and developing country vaccine manufacturers, UNICEF, the World Bank, civil society organizations and others to guarantee fair and equitable access to the vaccine for every country in the world.

COVAX currently includes more than 190 participating economies.

The stock rallied 10.07% to $292 in after-hours trading.

<h3>Travere&#39; Rare Kidney Disorder Drug Gets Orphan Drug Designation</h3>

Travere Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/TVTX#NASDAQ">TVTX</a>) said the European Commission has granted orphan designation to sparsentan for the treatment of IgA nephropathy, a rare kidney disorder and a leading cause of end-stage kidney disease.

Sparsentan is currently being evaluated in a pivotal Phase 3 clinical study for the treatment of IgAN, as well as a pivotal Phase 3 clinical study for the treatment of focal segmental glomerulosclerosis.

Topline data from the interim proteinuria assessment in the ongoing PROTECT Study of sparsentan in IgAN remain on track to be reported in the third quarter, Travere said.

The stock was up 2.69% to $30.50 in after-hours trading.

<h3>Pfizer/BioNTech Submit New Data to FDA Showing Stability of Coronavirus Vaccine at Standard Freezer Temperature</h3>

Pfizer Inc. (NYSE:<a class="ticker" href="/stock/PFE#NYSE">PFE</a>) and BioNTech SE &ndash; ADR (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>) announced the submission of new data to the FDA, demonstrating the stability of their COVID-19 vaccine when stored at -25 degrees centigrade to -15 degrees centigrade, temperatures more commonly found in pharmaceutical freezers and refrigerators.

The data have been submitted to the FDA to support a proposed update to the U.S. emergency use authorization prescribing Information, which would allow for vaccine vials to be stored at these temperatures for a total of two weeks as an alternative or complement to storage in an ultra-low temperature freezer, they said.

<h3>Viveve Expects Q4 Revenues to Exceed Consensus</h3>

Viveve Medical Inc (NASDAQ:<a class="ticker" href="/stock/VIVE#NASDAQ">VIVE</a>) announced preliminary fourth-quarter revenues of $1.9 million, above the $1.65-million consensus estimate. Additionally, the company said it expects a continued reduction in operating expenses, and a strengthened cash position following the close of its recent upsized financing of $27.6 million.

It is positioned with the capital resources to support operations through year-end 2022, including the planned completion of its pivotal U.S. PURSUIT trial in stress urinary incontinence.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/01/19387602/attention-biotech-investors-mark-your-calendar-for-february-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates </a>

<h3>Precision Announces Publication of Positive Long-term Animal Testing Data For Gene Editing Technology In Lowering Cholesterol</h3>

Precision BioSciences Inc (NASDAQ:<a class="ticker" href="/stock/DTIL#NASDAQ">DTIL</a>) announced the publication of a paper in Molecular Therapy describing three-year follow-up data showing long-term stable reduction of low-density lipoprotein cholesterol levels in non-human primates following in vivo gene editing of the PCSK9 gene with its proprietary ARCUS genome editing platform.

The stock was adding 1.50% to $11.50 in premarket trading Friday.

<h3>Immunocore&#39;s Tebentafusp Gets Breakthrough Therapy Designation For Treating Melanoma of Eye</h3>

Immunocore Holdings PLC &ndash; ADR (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>) said the FDA granted breakthrough therapy designation for tebentafusp for the treatment of HLA-A&#x2A;02:01-positive adult patients with unresectable or metastatic uveal melanoma

<h3>Dr. Reddy&#39;s Begins Rolling Submission For Regulatory Review of Russia-developed COVID-19 Vaccine In India</h3>

Dr.Reddy&#39;s Laboratories Ltd (NYSE:<a class="ticker" href="/stock/RDY#NYSE">RDY</a>) said it has initiated the process with the Drugs Controller General of India for emergency use authorization of human adenoviral vector-based platform vaccine candidate, Sputnik V.

The company said as part of the review process, it will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by Feb. 21.

Sputnik V is developed by Russia&#39;s Gamaleya National Research Institute of Epidemiology.

<h3>Oncorus Rises On Insider Buying</h3>

Oncorus Inc (NASDAQ:<a class="ticker" href="/stock/ONCR#NASDAQ">ONCR</a>) shares rallied after a Form-4 filing with the SEC revealed James Flynn, one of the directors of the company&#39;s board, bought 300,000 shares in the company in three transactions, priced at $19 apiece.

In after-hours trading, the stock was up 6.49% to $17.24.

<h3>Landos Gains On Disclosure of Fund Stake</h3>

Landos Biopharma Inc (NASDAQ:<a class="ticker" href="/stock/LABP#NASDAQ">LABP</a>) shares advanced after a 13D filing showed that Perceptive Advisors LLC beneficially owned 17.96 million shares in the company, giving it a stake of 45.9%. 
The stock gained 5.47% to $15.05 in after-hours trading.

<h3>Earnings</h3>

Quidel Corporation&#39;s(NASDAQ:<a class="ticker" href="/stock/QDEL#NASDAQ">QDEL</a>) fourth-quarter revenues climbed 432% year-over-year to $809.2 million, with bulk of the revenues coming from COVID-19 products. Non-GAAP EPS climbed from $1 in 2019 to $11.07 in 2020, while analysts, on average, estimated $10.14 per share.

In after-hours trading, the stock moved down 5.76% to $198.

Opko Health Inc. (NASDAQ:<a class="ticker" href="/stock/OPK#NASDAQ">OPK</a>) said its fourth-quarter revenues more than doubled from $224.3 million in 2019 to $494.6 million in 2020. The company reversed to a profit of 5 cents per share from a loss of 18 cents per share. The consensus estimate called for EPS of 4 cents.

In after-hours trading, the stock lost 4.11% to $5.14.

<h3>Offerings</h3>

Clearpoint Neuro Inc (NASDAQ:<a class="ticker" href="/stock/CLPT#NASDAQ">CLPT</a>) priced its underwritten public offering of 1.85 million shares of its common stock at a price of $23.50 per share. All the shares are being offered by the company. The offering is expected to close on Feb. 23, subject to customary closing conditions.

The stock slipped 4.65% to $24.60 in after-hours trading.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Insmed Incorporated (NASDAQ:<a class="ticker" href="/stock/INSM#NASDAQ">INSM</a>) will release topline data from its Phase 1 healthy volunteer trial of treprostinil palmitil inhalation powder, which is being evaluated for the treatment of patients with pulmonary arterial hypertension and other rare and serious pulmonary disorders.

Guidance

Offerings

Contracts

Pre-Market Outlook

The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs March 4)

<ul>
	<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="/stock/ATRC#NASDAQ">ATRC</a>)</li>
	<li>Five Prime Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FPRX#NASDAQ">FPRX</a>) -&nbsp;<a href="https://www.benzinga.com/general/biotech/21/03/20007289/amgen-pays-1-9b-for-five-prime-therapeutics-acquisition">announced </a> a deal to be bought by Amgen Inc. (NASDAQ:<a class="ticker" href="/stock/AMGN#NASDAQ">AMGN</a>) for $1.9 billion</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows March 4)

<ul>
	<li>AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="/stock/ABCL#NASDAQ">ABCL</a>)</li>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>)</li>
	<li>ADC Therapeutics SA (NYSE:<a class="ticker" href="/stock/ADCT#NYSE">ADCT</a>)</li>
	<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="/stock/APTO#NASDAQ">APTO</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Athenex, Inc. (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="/stock/BVS#NASDAQ">BVS</a>)</li>
	<li>Brainstorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/BCLI#NASDAQ">BCLI</a>)</li>
	<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="/stock/BCTX#NASDAQ">BCTX</a>)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DYN#NASDAQ">DYN</a>) (reacted to fourth-quarter results)</li>
	<li>Epizyme, Inc. (NASDAQ:<a class="ticker" href="/stock/EPZM#NASDAQ">EPZM</a>)</li>
	<li>Freeline Therapeutics Holdings plc (NASDAQ:<a class="ticker" href="/stock/FRLN#NASDAQ">FRLN</a>)</li>
	<li>Galecto, Inc. (NASDAQ:<a class="ticker" href="/stock/GLTO#NASDAQ">GLTO</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>Intercept Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ICPT#NASDAQ">ICPT</a>)</li>
	<li>Karyopharm Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="/stock/LEGN#NASDAQ">LEGN</a>)</li>
	<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="/stock/LQDA#NASDAQ">LQDA</a>)</li>
	<li>Lucira Health Inc (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>)</li>
	<li>Nabriva Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/NBRV#NASDAQ">NBRV</a>)</li>
	<li>Nanobiotix S.A. (NASDAQ:<a class="ticker" href="/stock/NBTX#NASDAQ">NBTX</a>)</li>
	<li>NeuroBo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/NRBO#NASDAQ">NRBO</a>)</li>
	<li>NexImmune, Inc. (NASDAQ:<a class="ticker" href="/stock/NEXI#NASDAQ">NEXI</a>)</li>
	<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="/stock/NLSP#NASDAQ">NLSP</a>)</li>
	<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/OLMA#NASDAQ">OLMA</a>)</li>
	<li>Oncorus, Inc. (NASDAQ:<a class="ticker" href="/stock/ONCR#NASDAQ">ONCR</a>)</li>
	<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/TARA#NASDAQ">TARA</a>)</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>)</li>
	<li>Repro Med Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/KRMD#NASDAQ">KRMD</a>)</li>
	<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="/stock/SANA#NASDAQ">SANA</a>)</li>
	<li>Sensei Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SNSE#NASDAQ">SNSE</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/SONN#NASDAQ">SONN</a>)</li>
	<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="/stock/TLIS#NASDAQ">TLIS</a>)</li>
	<li>uniQure N.V. (NASDAQ:<a class="ticker" href="/stock/QURE#NASDAQ">QURE</a>)</li>
	<li>Vallon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/VLON#NASDAQ">VLON</a>)</li>
	<li>Virios Therapeutics, LLC (NASDAQ:<a class="ticker" href="/stock/VIRI#NASDAQ">VIRI</a>)</li>
	<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/VRPX#NASDAQ">VRPX</a>)</li>
	<li>Viveve Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/VIVE#NASDAQ">VIVE</a>)</li>
	<li>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/VYGR#NASDAQ">VYGR</a>)</li>
	<li>Yumanity Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMTX#NASDAQ">YMTX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Moderna&#39;s Japanese Partner Takeda Submits New Drug Application For Coronavirus Vaccine In Japan</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) said its Japanese partner Takeda Pharmaceutical Company Limited (NYSE:<a class="ticker" href="/stock/TAK#NYSE">TAK</a>) submitted a new drug application to Japan&#39;s Ministry of Health, Labour and Welfare to import and distribute Moderna&#39;s vaccine candidate against COVID-19 in Japan.

Takeda is conducting a placebo-controlled Phase 1/2 study designed to evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 at the 100 &mu;g dose level given 28 days apart in 200 participants aged 20 years and above in Japan.

In October, the two companies <a href="https://www.benzinga.com/general/biotech/20/10/18114632/the-daily-biotech-pulse-novartis-acquires-gene-therapy-company-modernas-japanese-vaccine-supply-d">entered </a> into a pact under which Moderna will supply 50 million doses of its vaccine to Takeda for distribution in Japan.

Moderna shares were down 1.81% to $130.49 in premarket trading Friday.

<h3>Roche&#39;s Biologics Products Gets FDA Nod For Lung Disease</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) said the FDA approved Actemra/RoActemra&nbsp;subcutaneous injection&nbsp;for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease, a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease.

<h3>Sigilon&#39;s SIG-007 Gets Orphan Drug Designation For Fabry Disease</h3>

Sigilon said the FDA has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/02/19887970/the-week-ahead-in-biotech-feb-28-march-6-kempharm-gilead-fda-decisions-and-more-earnings"> The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings </a>

<h3>ALX Oncology to Collaborate With Tallac For Developing Cancer Immunotherapies</h3>

ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="/stock/ALXO#NASDAQ">ALXO</a>) announced a collaboration with privately held Tallac Therapeutics to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of R&amp;D and any profits or losses incurred.

The companies said they will leverage their respective scientific and technical expertise to advance an anti-SIRP&alpha; antibody conjugated to a Toll-like receptor 9 agonist for targeted activation of both the innate and adaptive immune systems.

<h3>Apellis Shelves Study Of APL-9 In Severe COVID-19 Patients</h3>

Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/APLS#NASDAQ">APLS</a>) said it will not pursue additional development of APL-9, an investigational targeted C3 therapy designed for acute interventions, for the treatment of severe COVID-19. The decision followed an interim review of mortality data from the Phase 1/2 study by an independent data monitoring committee, which found no meaningful reduction in the overall mortality rate in patients treated with APL-9 in combination with standard of care therapy compared to standard of care alone. No safety signals were observed by the DMC.

The stock fell 1.42% to $45 in after-hours trading.

<h3>Ocular Therapeutix&nbsp;Application For Dextenza Label Expansion Accepted For Review</h3>

Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="/stock/OCUL#NASDAQ">OCUL</a>) announced the supplemental new drug application for Dextenza 0.4 mg for intracanalicular use, has been accepted for review by the FDA. The FDA has set an action date under the Prescription Drug User Fee Act of no later than Oct. 18. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication of Dextenza.

The stock rose 2.42% to $17.75 in after-hours trading.

<h3>Earnings</h3>

Fulgent Genetics, Inc. (NASDAQ:<a class="ticker" href="/stock/FLGT#NASDAQ">FLGT</a>) reported fourth-quarter revenues of $295 million, up over 3,400% year-over-year. The non-GAAP net income came in at $6.20 per share, ahead of the $4.02 per share estimated by analysts.

The stock jumped 34.46% to $115 in after-hours trading.

Acorda Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/ACOR#NASDAQ">ACOR</a>) reported fiscal-year 2020 fourth-quarter revenues of $38.16 million, down from $50.50 million a year-ago. The company reversed to a loss per share of $9.82 from a profit of $8.26 per share. 
The stock slipped 11.5% to $6 in after-hours trading.

Opiant Pharmaceuticals Inc&#39;s (NASDAQ:<a class="ticker" href="/stock/OPNT#NASDAQ">OPNT</a>) fourth-quarter revenues climbed from $7.67 million in 2019 to $9.924 million in 2020. The company reversed to a loss of 16 cents per share from a profit of 20 cents per share. The consensus estimates had called for a profit of 7 cents per share on revenues of $9.92 million.

In after-hours trading, the stock rose 5.34% to $14.

DermTech Inc (NASDAQ:<a class="ticker" href="/stock/DMTK#NASDAQ">DMTK</a>) said its fourth-quarter revenues increased 33% year-over-year to $2.1 million. The net loss per share widened from 48 cents to 43 cents.

The company said it estimates that first-quarter assay revenue will be between $1.6 and $1.9 million.

The stock moved down 7.95% to $48.77 in after-hours trading.

<h3>On The Radar</h3>

<h3>PDUFA Dates</h3>

The FDA will decide on the approvability of Gilead Sciences, Inc.&#39;s (NASDAQ:<a class="ticker" href="/stock/GILD#NASDAQ">GILD</a>) Yescarta, or axicabtagene ciloleucel, which is being evaluated for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma after two or more prior lines of systemic therapy. Yescarta is a CAR T-cell therapy that came into Gilead&#39;s stable through its Kite purchase.&nbsp;

<h3>Earnings</h3>

<ul>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>) (before the market open)</li>
	<li>Oncolytics Biotech Inc. (NASDAQ:<a class="ticker" href="/stock/ONCY#NASDAQ">ONCY</a>) (before the market open)</li>
</ul>

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/02/19899559/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates </a>

The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study

BIOPHYTIS SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) announces that the independent Data Monitoring Committee (DMC) for the COVA study has delivered a favorable opinion on the safety of Sarconeos (BIO101) in patients infected with COVID-19, following the scheduled interim analysis of the 50 participants from Part 1 of the study, as well as the progression of patients enrollment, which has now reached 97 of the 155 planned for the second interim analysis.

A total of 28 clinical centers of the 30 targeted are now opened and recruiting in the United States, Brazil, France and Belgium. Upon the second interim analysis, based on the safety and efficacy data from 155 patients, the DMC will re assess the total size of the cohort, estimated today at 310 patients, and the continuation of the trial.

Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: "In the persistent pressured healthcare context of COVID-19, we are extremely pleased with the opinion delivered by the DMC on the safety of Sarconeos (BIO101) in the framework of our COVA trial. This opinion allows us to push our mission forward with continued recruitment into Part 2 of the COVA study. We have now enrolled 97 out of the targeted 155 participants planned for the second interim analysis. Our 28 sites are recruiting in the United States, Brazil, France and Belgium. Our next milestone is now the second interim analysis, where we will get from DMC the green light for continuing our trial, as well as the final number of patients needed for the study".

The COVA clinical program (clinicaltrials.gov identifier NCT04472728) is a global, multicenter, double-blind, placebo-controlled, group-sequential and adaptive design two-part study. It is a Phase 2-3 study that assesses Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations of COVID-19

Part 1 of the COVA Study is a Phase 2 exploratory proof of concept study providing preliminary data on the safety, tolerability and activity of Sarconeos (BIO101) in 50 hospitalized patients with severe respiratory manifestations related to COVID-19.

Part 2 of the COVA Study is a Phase 3 randomized study investigating the safety and efficacy of Sarconeos (BIO101) on the respiratory function of 310 COVID-19 patients (including the 50 patients from Part 1 of the study).

The study results (Part 1 and Part 2) are expected in Q2 2021, subject to any COVID-19-related delays and the impact of the current pandemic.

BIOPHYTIS Independent Data Monitoring Committee Delivered Favorable Opinion for its Phase 2-3 COVA Study on COVID-19

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Seneca Biopharma (NASDAQ:<a class="ticker" href="/stock/SNCA#NASDAQ">SNCA</a>) shares increased by 34.14% to $2.2 during Monday&#39;s pre-market session. The market value of their outstanding shares is at $38.0 million.</li>
	<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="/stock/MRKR#NASDAQ">MRKR</a>) shares rose 19.42% to $2.89. The market value of their outstanding shares is at $239.9 million.</li>
	<li>Acer Therapeutics (NASDAQ:<a class="ticker" href="/stock/ACER#NASDAQ">ACER</a>) shares rose 18.49% to $4.1. The company&#39;s market cap stands at $58.6 million.</li>
	<li>Edesa Biotech (NASDAQ:<a class="ticker" href="/stock/EDSA#NASDAQ">EDSA</a>) stock moved upwards by 17.12% to $6.43. The market value of their outstanding shares is at $84.7 million.</li>
	<li>Sesen Bio (NASDAQ:<a class="ticker" href="/stock/SESN#NASDAQ">SESN</a>) stock increased by 16.04% to $3.76. The market value of their outstanding shares is at $630.0 million.</li>
	<li>BioCryst Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/BCRX#NASDAQ">BCRX</a>) shares increased by 15.18% to $15.25. The market value of their outstanding shares is at $2.7 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="/stock/CMMB#NASDAQ">CMMB</a>) shares fell 12.6% to $44.5 during Monday&#39;s pre-market session.</li>
	<li>SenesTech (NASDAQ:<a class="ticker" href="/stock/SNES#NASDAQ">SNES</a>) stock decreased by 11.02% to $2.02. The market value of their outstanding shares is at $16.2 million.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) shares fell 10.05% to $14.5.</li>
	<li>SCWorx (NASDAQ:<a class="ticker" href="/stock/WORX#NASDAQ">WORX</a>) stock decreased by 7.91% to $1.98. The market value of their outstanding shares is at $19.5 million.</li>
	<li>Genesis Healthcare (NYSE:<a class="ticker" href="/stock/GEN#NYSE">GEN</a>) stock decreased by 5.84% to $0.56. The market value of their outstanding shares is at $94.5 million.</li>
	<li>Catabasis Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/CATB#NASDAQ">CATB</a>) shares declined by 5.22% to $3.27. The market value of their outstanding shares is at $76.5 million.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Monday's Pre-Market Session

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs March 24)

<ul>
	<li>F-star Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FSTX#NASDAQ">FSTX</a>)</li>
	<li>IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/IDYA#NASDAQ">IDYA</a>)</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="/stock/ORPH#NASDAQ">ORPH</a>)</li>
	<li>Ortho Clinical Diagnostics Holdings plc (NASDAQ:<a class="ticker" href="/stock/OCDX#NASDAQ">OCDX</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows March 24)

<ul>
	<li>Adagene Inc. (NASDAQ:<a class="ticker" href="/stock/ADAG#NASDAQ">ADAG</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="/stock/CNTB#NASDAQ">CNTB</a>) (went public Friday)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DYN#NASDAQ">DYN</a>)</li>
	<li>Epizyme, Inc. (NASDAQ:<a class="ticker" href="/stock/EPZM#NASDAQ">EPZM</a>)</li>
	<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="/stock/EVAX#NASDAQ">EVAX</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FNCH#NASDAQ">FNCH</a>) (went public Friday)</li>
	<li>Forma Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/FMTX#NASDAQ">FMTX</a>)</li>
	<li>Galapagos NV (NASDAQ:<a class="ticker" href="/stock/GLPG#NASDAQ">GLPG</a>)</li>
	<li>Galecto, Inc. (NASDAQ:<a class="ticker" href="/stock/GLTO#NASDAQ">GLTO</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>Ibere Pharmaceuticals (NYSE:<a class="ticker" href="/stock/IBER#NYSE">IBER</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>MorphoSys AG (NASDAQ:<a class="ticker" href="/stock/MOR#NASDAQ">MOR</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Odonate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ODT#NASDAQ">ODT</a>)</li>
	<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/OLMA#NASDAQ">OLMA</a>)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="/stock/TLIS#NASDAQ">TLIS</a>)</li>
	<li>uniQure N.V. (NASDAQ:<a class="ticker" href="/stock/QURE#NASDAQ">QURE</a>)</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>)</li>
	<li>Vallon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/VLON#NASDAQ">VLON</a>)</li>
	<li>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/VYGR#NASDAQ">VYGR</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Neurocrine to Join S&amp;P MidCap 400 Index</h3>

Standard &amp; Poor&#39;s announced that Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/NBIX#NASDAQ">NBIX</a>) will replace O-I Glass Inc. (NYSE:<a class="ticker" href="/stock/OI#NYSE">OI</a>) in the S&amp;P MidCap 400&nbsp;effective March 30.

The stock was up 8.98% premarket at $95.43.&nbsp;

<h3>Cellect Biotech to Merge With Specialty Pharma Company Quoin</h3>

Cellect Biotechnology Ltd. (NASDAQ:<a class="ticker" href="/stock/APOP#NASDAQ">APOP</a>) announced a merger agreement with privately held specialty pharma company Quoin Pharmaceuticals Inc. The agreement provides for Cellect shareholders owning 25% of the combined company compared to 75% by Quoin shareholders.

Completion of the merger is subject to approval of shareholders of both companies and certain other conditions. The closing of the transaction is expected by the end of the second quarter of 2021. Following the completion of the merger, Cellect will be renamed Quoin Pharmaceuticals and will begin trading on NASDAQ under the symbol QNRX.

The stock was up 45.85% premarket at $5.09.&nbsp;

<h3>Midatech Announces Term Agreement To Co-Develop MTX110</h3>

Midatech Pharma plc (NASDAQ:<a class="ticker" href="/stock/MTP#NASDAQ">MTP</a>) said the heads of terms of the agreement for codeveloping MTX110 has been agreed, and if the deal progresses to definitive agreements, the company said it expects to receive a modest upfront payment on execution, success-based development and sales milestones and royalties.

The company also released headline unaudited results, showing lower revenues and a wider loss for fiscal year 2020.

The stock was up 3.41% to $2.12&nbsp;in premarket trading Thursday.

<h3>Vertex Announces Australian Regulatory Nod For Triple Combo Cystic Fibrosis Therapy</h3>

Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="/stock/VRTX#NASDAQ">VRTX</a>) said the Australian Therapeutic Goods Administration has approved the use of <a href="https://www.benzinga.com/general/biotech/20/01/15121064/7-blockbuster-drugs-expected-to-be-launched-in-2020">Trikafta </a> for people with cystic fibrosis, ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene, the most common CF-causing mutation worldwide.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/03/20261034/fda-decisions-for-pfizer-eli-lilly-and-bluebird-bio-bristol-meyers-squibb-plus-new-data-and-earni?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29"> FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings&nbsp;</a>

<h3>Bristol-Myers Squibb Opdivo-Antibody Combo Therapy Aces Phase 2/3 Skin Cancer Study</h3>

Bristol-Myers Squibb (NYSE:<a class="ticker" href="/stock/BMY#NYSE">BMY</a>) announced positive primary results from the Phase 2/3 trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma.

The company said the trial met its primary endpoint of progression-free survival. Follow-up for overall survival, a secondary endpoint, is ongoing. Additionally, the fixed-dose combination was well-tolerated and there were no new safety signals reported in either the relatlimab and Opdivo combination arm or the Opdivo arm.

<h3>G1&#39;s Recently Approved Cosela Included In 2 Updated Cancer Treatment Guidelines</h3>

G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GTHX#NASDAQ">GTHX</a>) said its Cosela has been added to two updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: the Treatment Guidelines for Small Cell Lung Cancer and the Supportive Care Guidelines for Hematopoietic Growth Factors.

It recently won the <a href="https://www.benzinga.com/general/biotech/21/02/19667444/g1-therapeutics-trilaciclib-wins-fda-nod-for-mitigating-chemo-effects-in-lung-cancer-patients">FDA nod </a> for mitigating the effects of chemotherapy in lung cancer patients.

The stock was up 1.76% at $20.80 in premarket trading Thursday.

<h3>Synlogic Says Hyperoxaluria Treatment Achieves Proof of Mechanism In Phase 1 Study</h3>

Synlogic, Inc. (NASDAQ:<a class="ticker" href="/stock/SYBX#NASDAQ">SYBX</a>) announced that SYNB8802 has achieved proof of mechanism in a dietary hyperoxaluria Phase 1 Part A study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.

In the study&#39;s efficacy analysis, the percent change from baseline urinary oxalate levels were negative 28.6% compared to placebo, at the 3e11 live cell dose. This dose was well tolerated and will be used in Part B of the study, the company said.

The stock was down 6.96% premarket at $3.61.&nbsp;

<h3>Radius, Sio-Gene Gain On Insider Transactions</h3>

Radius Health, Inc. (NASDAQ:<a class="ticker" href="/stock/RDUS#NASDAQ">RDUS</a>) said in a filing its chief business officer Chhaya Shah exercised options to buy shares.

Sio Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="/stock/SIOX#NASDAQ">SIOX</a>) revealed in a filing its CEO Pawan Cheruvu bought 100,000 shares in the company at $2.4814.

In after-hours trading, Radius stock was up 19.49% to $27.50, while Sio Gene gained 8.97% to $2.55.

<h3>Earnings</h3>

TELA Bio, Inc.&#39;s (NASDAQ:<a class="ticker" href="/stock/TELA#NASDAQ">TELA</a>) fourth-quarter revenue&nbsp;climbed 17% year-over-year to $5.7 million in 2020, and the loss per share narrowed from $1.22 to 54 cents.

The stock climbed 14.29% to $16 in after-hours trading.

<h3>Offerings</h3>

Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>) priced its underwritten public offering of 17.143 million shares of its common stock at a price to $1.75 per share. The gross proceeds from the offering to Evofem are expected to be approximately $30 million. The offering is expected to close on or about March 29. All of the shares of common stock in the offering are to be sold by Evofem.

In after-hours trading, the stock fell 10.73% to $2.08.

<h3>On The Radar</h3>

<h3>Adcom Meeting</h3>

The FDA&#39;s Arthritis Advisory Committee, along with the Drug Safety and Risk Management Advisory Committee will likely announce its recommendation on Pfizer Inc.&#39;s (NYSE:<a class="ticker" href="/stock/PFE#NYSE">PFE</a>) biologic license application for tanezumab subcutaneous injection for the proposed indication of relief of signs and symptoms of moderate to severe osteoarthritis in adult patients for whom use of other analgesics is ineffective or not appropriate. Tanezumab is being jointly developed by Pfizer and Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>).

<h3>Earnings</h3>

<ul>
	<li>Vascular Biogenics Ltd. (NASDAQ:<a class="ticker" href="/stock/VBLT#NASDAQ">VBLT</a>) (before the market open)</li>
	<li>Genetron Holdings Limited (NASDAQ:<a class="ticker" href="/stock/GTH#NASDAQ">GTH</a>) (before the market open)</li>
	<li>Synlogic (before the market open)</li>
	<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="/stock/NBY#NYSE">NBY</a>) (after the close)</li>
	<li>Neoleukin Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NLTX#NASDAQ">NLTX</a>) (after the close)</li>
	<li>OpGen, Inc. (NASDAQ:<a class="ticker" href="/stock/OPGN#NASDAQ">OPGN</a>) (after the close)</li>
	<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="/stock/EYEN#NASDAQ">EYEN</a>) (after the close)</li>
	<li>HTG Molecular Diagnostics, Inc. (NASDAQ:<a class="ticker" href="/stock/HTGM#NASDAQ">HTGM</a>) (after the close)</li>
	<li>CymaBay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/CBAY#NASDAQ">CBAY</a>) (after the close)</li>
	<li>BIOLASE, Inc. (NASDAQ:<a class="ticker" href="/stock/BIOL#NASDAQ">BIOL</a>) (after the close)</li>
	<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="/stock/ADMA#NASDAQ">ADMA</a>) (after the close)</li>
	<li>Athersys, Inc. (NASDAQ:<a class="ticker" href="/stock/ATHX#NASDAQ">ATHX</a>) (after the close)</li>
	<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/PCSA#NASDAQ">PCSA</a>)</li>
	<li>Panbela Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/PBLA#NASDAQ">PBLA</a>)</li>
</ul>

<h3>IPOs</h3>

Dutch biotechnology Lava Therapeutics B.V., which is developing bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells, priced its 6.7-million share initial public offering at $15, the midpoint of the estimated price range of $14-$16. The company&#39;s shares will begin trading on the Nasdaq under the ticker symbol LVTX.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/02/19899559/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates </a>

The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs March 25)

<ul>
	<li>Cellect Biotechnology Ltd. (NASDAQ:<a class="ticker" href="/stock/APOP#NASDAQ">APOP</a>) (<a href=" https://www.benzinga.com/general/biotech/21/03/20342985/why-cellect-immutep-f-star-proqr-and-evofem-are-moving-thursday"> announced </a> a reverse merger)</li>
	<li>GenMark Diagnostics, Inc. (NASDAQ:<a class="ticker" href="/stock/GNMK#NASDAQ">GNMK</a>) (Roche Holding AG (OTC: <a class="ticker" href="https://www.benzinga.com/stock/rhhby#OTC">RHHBY</a>) commenced tender offer to <a href=" https://www.benzinga.com/general/biotech/21/03/20160023/roche-boosts-diagnostics-portfolio-with-1-8b-bet-on-covid-19-test-manufacturer-genmark"> buy </a> the diagnostic company)</li>
	<li>Ibere Pharmaceuticals (NYSE:<a class="ticker" href="/stock/IBER#NYSE">IBER</a>)</li>
	<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="/stock/PRQR#NASDAQ">PRQR</a>) (follow-through buying from a positive readout from Wednesday)</li>
	<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="/stock/PRTA#NASDAQ">PRTA</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows March 25)

<ul>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RNA#NASDAQ">RNA</a>)</li>
	<li>Biofrontera AG (NASDAQ:<a class="ticker" href="/stock/BFRA#NASDAQ">BFRA</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation CFRX)</li>
	<li>Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="/stock/CNTB#NASDAQ">CNTB</a>) (IPOed Friday)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Epizyme, Inc. (NASDAQ:<a class="ticker" href="/stock/EPZM#NASDAQ">EPZM</a>)</li>
	<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="/stock/EVAX#NASDAQ">EVAX</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>) (priced a common stock offering)</li>
	<li>Forma Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/FMTX#NASDAQ">FMTX</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Galapagos NV (NASDAQ:<a class="ticker" href="/stock/GLPG#NASDAQ">GLPG</a>)</li>
	<li>Galecto, Inc. (NASDAQ:<a class="ticker" href="/stock/GLTO#NASDAQ">GLTO</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="/stock/LGVN#NASDAQ">LGVN</a>)</li>
	<li>MorphoSys AG (NASDAQ:<a class="ticker" href="/stock/MOR#NASDAQ">MOR</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Odonate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ODT#NASDAQ">ODT</a>)</li>
	<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/OLMA#NASDAQ">OLMA</a>)</li>
	<li>Oncorus, Inc. (NASDAQ:<a class="ticker" href="/stock/ONCR#NASDAQ">ONCR</a>)</li>
	<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="/stock/PHAR#NASDAQ">PHAR</a>)</li>
	<li>Prometheus Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RXDX#NASDAQ">RXDX</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/SPRB#NASDAQ">SPRB</a>)</li>
	<li>Talis Biomedical Corporation (NASDAQ:<a class="ticker" href="/stock/TLIS#NASDAQ">TLIS</a>)</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>)</li>
	<li>Vallon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/VLON#NASDAQ">VLON</a>)</li>
	<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/VRPX#NASDAQ">VRPX</a>)</li>
	<li>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/VYGR#NASDAQ">VYGR</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Astellas Gets Label Expansion For Bladder Dysfunction Drug</h3>

Astellas Pharma Inc. (OTC:<a class="ticker" href="/stock/ALPMY#OTC">ALPMY</a>) said the Food and Drug Administration approved a new indication for Myrbetriq and Myrbetriq Granules to treat a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.

<h3>Gilead&#39; Breast Cancer Drug Application Validated By European Regulator</h3>

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/GILD#NASDAQ">GILD</a>) announced that the European Medicines Agency validated the marketing authorization application for sacituzumab govitecan-hziy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, who have received at least two prior therapies.

The MAA is now under accelerated review by the EMA, in recognition of the product being considered of major interest for public health and therapeutic innovation.

Sacituzumab govitecan-hziy is an antibody-drug conjugate that came into Gilead&#39;s stable through its acquisition of Immunomedics.

<h3>Seagan, Astellas Announce EMA Acceptance of Regulatory Application For Cancer Antibody-drug Conjugate</h3>

Seagen Inc. (NASDAQ:<a class="ticker" href="/stock/SGEN#NASDAQ">SGEN</a>) and Astellas announced the EMA accepted the MAA for enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatments. If approved, enfortumab vedotin would be the first antibody-drug conjugate available in the European Union for people living with urothelial cancer, the companies said.

Seagen shares were adding 2.83% to $143.22 in premarket trading Friday.

<h3>Earnings</h3>

Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="/stock/PHIO#NASDAQ">PHIO</a>) said the loss narrowed from $19.33 per share in 2019 to $1.92 per share in 2020, in line with the consensus estimate.

The stock rose 7.30% to $2.94 in after-hours trading.

BIOLASE, Inc. (NASDAQ:<a class="ticker" href="/stock/BIOL#NASDAQ">BIOL</a>) reported fourth-quarter revenues of $8.52 million, down 16.3% year-over-year. The loss per share, however, narrowed from 13 cents to 7 cents. Analysts estimated a narrower loss of 4 cents per share.

The stock was down 3.83% to 92.3 cents in premarket trading Friday.

Athersys, Inc.&#39;s (NASDAQ:<a class="ticker" href="/stock/ATHX#NASDAQ">ATHX</a>) fourth-quarter revenues increased from $0.3 million in 2019 to $1.3 million in 2020. The loss per share, though widening from 6 cents to 11 cents, was in line with the consensus estimate.

In premarket trading Friday, Athersys shares were advancing 4.60% to $1.82.

Vivos Therapeutics, Inc. (NASDA: VVOS) said its fourth-quarter revenues climbed from $3.1 million in 2019 to $3.3 million in 2020. The net loss per share widened from $2.6 million to $6.2 million.

The stock was gaining 9.65% to $7.50 in premarket trading Friday.

<h3>On The Radar</h3>

<h3>IPOs</h3>

Design Therapeutics, Inc., a biotech developing a platform of gene-targeted chimera small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, priced its initial public offering of 12 million shares of its common stock at $20 per share. The gross proceeds from the offering are expected to be $240 million.

The shares are expected to begin trading on the Nasdaq under the ticker symbol DSGN.

Edgewise Therapeutics, Inc. priced its IPO of 11 million shares at a price of $16 per share, for raising gross proceeds of $176 million. Edgewise is a clinical-stage biopharma focused on developing orally bioavailable, small molecule therapies for rare muscle disorders.

The shares will begin trading on the Nasdaq under the ticker symbol EWTX.

Ikena Oncology, Inc., a targeted oncology company focused on developing cancer therapies targeting key signaling pathways, priced its IPO of 7.8125 million shares of common stock at $16 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol IKNA.

The gross proceeds of the offering are expected to be $125 million.

The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs March 31)

<ul>
	<li>AngioDynamics, Inc. (NYSE:<a class="ticker" href="/stock/ANGO#NYSE">ANGO</a>)</li>
	<li>Axonics Modulation Technologies, Inc. (NYSE:<a class="ticker" href="/stock/AXNX#NYSE">AXNX</a>)</li>
	<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GANX#NASDAQ">GANX</a>)</li>
	<li>Laboratory Corporation of America Holdings (NYSE:<a class="ticker" href="/stock/LH#NYSE">LH</a>)</li>
	<li>Lava Therapeutics B.V. (NASDAQ:<a class="ticker" href="/stock/LVTX#NASDAQ">LVTX</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>PPD, Inc. (NASDAQ:<a class="ticker" href="/stock/PPD#NASDAQ">PPD</a>)</li>
	<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRDX#NASDAQ">SRDX</a>)</li>
	<li>Varian Medical Systems, Inc. (NYSE:<a class="ticker" href="/stock/VAR#NYSE">VAR</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows March 31)

<ul>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Nanobiotix S.A. (NASDAQ:<a class="ticker" href="/stock/NBTX#NASDAQ">NBTX</a>)</li>
	<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Sonoma Strikes Deal to Distribute&nbsp;Dermatology and Eye and Wound Care Products In U.S.</h3>

Sonoma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SNOA#NASDAQ">SNOA</a>) announced an agreement with EMC Pharma, giving the latter the exclusive right to distribute its HOCl-based prescription dermatology and eye care products in the U.S. for an initial term of five years, subject to extension.

EMC Pharma will also have a non-exclusive agreement to distribute certain Microcyn-based wound care products into government channels.

As part of the agreement, EMC will acquire all of the existing inventory and pay a royalty and transfer prices over the initial five-year term. The parties also agreed on certain minimum purchase requirements to maintain exclusivity of the distribution rights.

In after-hours trading, the stock gained 24.23% to $9.23.

<h3>BioXcel Reports Mixed Results For Phase 1b/2 Study of Drug to Treat Opioid Withdrawal Symptoms</h3>

BioXcel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BTAI#NASDAQ">BTAI</a>) announced positive topline results from the Phase 1b/2 proof-of-concept study of its investigational asset BXCL501 that is being evaluated for the treatment of opioid withdrawal symptoms.

The company said the study met its primary safety endpoint across multiple doses given twice-daily over seven days. BXCL501 was generally well tolerated, with no severe or serious adverse events reported, and dose dependent exposures were observed across all doses evaluated, it added.

However, the secondary endpoint of retention was not met with statistical significance.

The stock slipped 7.78% to $39.80 in after-hours trading.

<h3>Opiant Gets Final Tranche of $1.8 Million Award For Study of Opioid Overdose Drug</h3>

Opiant Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/OPNT#NASDAQ">OPNT</a>) said it has been has received the third and final tranche of $1.8 million from the total grant of approximately $7.4 million from the National Institute on Drug Abuse, part of the National Institutes of Health, to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose.

<h3>Ortho Clinical Diagnostics Gets $53.7M Contract For COVID-19 Testing Solutions</h3>

In-vitro diagnostics company Ortho Clinical Diagnostics (NASDAQ:<a class="ticker" href="/stock/OCDX#NASDAQ">OCDX</a>) said it has been awarded an undefinitized contract by the BARDA and the U.S. Department of Defense, which will lead to a $53.7 million award to support a more than three-fold increase in domestic production capabilities for its COVID-19 serological and diagnostic testing solutions.

The new contract, the company said, will deliver funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market by the second quarter of 2022.

The stock gained 4.95% to $20.25 in after-hours trading.

<h3>Rhythm Rises On Insider Buying</h3>

Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RYTM#NASDAQ">RYTM</a>) shares gained ground after the company revealed in a filing its CEO David Meeker bought 10,000 shares in the company for $20.1713 per share.

The stock added 5.55% to $22.45 in after-hours trading.

<h3>Atreca&#39;s Chief Scientific Officer Norman Greenberg Quits</h3>

Atreca, Inc. (NASDAQ:<a class="ticker" href="/stock/BCEL#NASDAQ">BCEL</a>) said in a filing its chief scientific officer Norman Greenberg has resigned, effective March 31, to pursue a new business opportunity. The company clarified that Greenberg&#39;s departure was not due to any disagreement with the company or any matters relating to its operations, policies or practices.

In after-hours trading, the stock slipped 6.98% to $14.26.

<h3>Pfizer, BioNTech Announces Positive Efficacy, Safety Data Through 6 Months Following Second COVID-19 vaccine dose</h3>

Pfizer Inc. (NYSE:<a class="ticker" href="/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, showing that the COVID-19 vaccine, <a href=" https://www.benzinga.com/analyst-ratings/analyst-color/21/03/20422700/pfizers-late-stage-covid-19-vaccine-data-in-adolescents-reinforces-bull-case-analys"> BNT162b2, </a> was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective against severe COVID-19 as defined by the FDA.

&quot;These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,&quot; said Albert Bourla, CEO of Pfizer.

<h3>BD, Abbott, Quidel Gets Emergency Use Authorizations For COVID-19 Tests</h3>

Becton, Dickinson and Company (NYSE:<a class="ticker" href="/stock/BDX#NYSE">BDX</a>) announced FDA has granted <a href="https://www.benzinga.com/government/20/04/15759780/what-is-fda-emergency-use-authorization">emergency use authorization</a>&nbsp;for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals.

Quidel Corporation (NASDAQ:<a class="ticker" href="/stock/QDEL#NASDAQ">QDEL</a>) received emergency use authorization for its at-home over-the-counter COVID-19 test. 
Abbott (NYSE:<a class="ticker" href="/stock/ABT#NYSE">ABT</a>) received emergency use nod for over-the-counter, non-prescription, asymptomatic use of its BinaxNOW COVID-19 Ag self-test for detection of COVID-19 infection.

<h3>Sanofi Gets FDA Approval For Blood Cancer Combo Treatment In Second-line Settings And Above</h3>

Sanofi SA&#39;s (NASDAQ:<a class="ticker" href="/stock/SNY#NASDAQ">SNY</a>) Sarclisa, in combination with carfilzomib and dexamethasone, was approved by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received one to three prior lines of therapy.

&quot;&quot;With this approval, Sarclisa is now included in two standard of care regimens for the treatment of patients with multiple myeloma as early as first relapse. Today&#39;s milestone further supports our ambition for Sarclisa to become the anti-CD38 of choice for patients with relapsed or refractory multiple myeloma,&quot; said Peter Adamson, Global Development Head, Oncology and Pediatric Innovation at Sanofi.

<h3>Offerings</h3>

Applied Molecular Transport Inc. (NASDAQ:<a class="ticker" href="/stock/AMTI#NASDAQ">AMTI</a>) priced an underwritten public offering of 2.5 million shares of its common stock at a price of $42 per share, for raising gross proceeds of about $105 million. All of the shares of common stock are being offered by AMT. The offering is expected to close on April 6, 2021, subject to the satisfaction of customary closing conditions.

The stock ended after-hours trading 0.82% lower at $43.65.

CTI BioPharma Corp. (NASDAQ:<a class="ticker" href="/stock/CTIC#NASDAQ">CTIC</a>) priced its previously announced underwritten public offering of 14.26 million shares of its common stock at $2.50 per share. The pricing of 600 shares of its series X preferred stock was set at $25,000. Each share of Series X preferred will be convertible into 10,000 shares of common stock at the election of the holder.

The stock fell 10.65% to $2.60 in after-hours trading.

<h3>On The Radar</h3>

<h3>Earnings</h3>

Milestone Scientific Inc. (NYSE:<a class="ticker" href="/stock/MLSS#NYSE">MLSS</a>) (after the close)

The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Odonate Therapeutics (NASDAQ:<a class="ticker" href="/stock/ODT#NASDAQ">ODT</a>) stock moved upwards by 17.63% to $4.07 during Wednesday&#39;s regular session. Trading volume for this security as of 12:32 EST is 112.9 million, which is 8043.53% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $157.1 million.</li>
	<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="/stock/COCP#NASDAQ">COCP</a>) stock rose 15.27% to $1.58. Trading volume for Cocrystal Pharma&#39;s stock is 4.8 million as of 12:32 EST. This is 176.01% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $112.8 million.</li>
	<li>Titan Medical (NASDAQ:<a class="ticker" href="/stock/TMDI#NASDAQ">TMDI</a>) shares increased by 15.08% to $2.06. The current volume of 31.1 million shares is 882.5% of Titan Medical&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The market value of their outstanding shares is at $225.6 million.</li>
	<li>Frequency Therapeutics (NASDAQ:<a class="ticker" href="/stock/FREQ#NASDAQ">FREQ</a>) shares moved upwards by 13.76% to $11.45. Frequency Therapeutics&#39;s stock is trading at a volume of 9.3 million shares as of 12:32 EST. This is 851.97% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $391.3 million.</li>
	<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="/stock/APDN#NASDAQ">APDN</a>) shares rose 12.79% to $8.2. As of 12:32 EST, Applied DNA Sciences&#39;s stock is trading at a volume of 8.7 million, which is 617.64% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $61.2 million.</li>
	<li>Ocugen (NASDAQ:<a class="ticker" href="/stock/OCGN#NASDAQ">OCGN</a>) shares increased by 12.78% to $7.16. Ocugen&#39;s stock is trading at a volume of 66.1 million shares as of 12:32 EST. This is 113.91% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.3 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>FibroGen (NASDAQ:<a class="ticker" href="/stock/FGEN#NASDAQ">FGEN</a>) shares decreased by 39.53% to $20.95 during Wednesday&#39;s regular session. Trading volume for FibroGen&#39;s stock is 12.6 million as of 12:32 EST. This is 1296.75% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.9 billion.</li>
	<li>Homology Medicines (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>) shares decreased by 18.39% to $7.59. The current volume of 3.1 million shares is 819.31% of Homology Medicines&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The company&#39;s market cap stands at $383.2 million.</li>
	<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="/stock/GALT#NASDAQ">GALT</a>) shares declined by 14.11% to $2.4. Trading volume for this security as of 12:32 EST is 1.4 million, which is 249.61% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $137.4 million.</li>
	<li>Vyant Bio (NASDAQ:<a class="ticker" href="/stock/VYNT#NASDAQ">VYNT</a>) shares decreased by 11.83% to $4.07. Trading volume for this security as of 12:32 EST is 266.5K, which is 83.26% of its average full-day volume over the last 100 days.</li>
	<li>Second Sight Medical (NASDAQ:<a class="ticker" href="/stock/EYES#NASDAQ">EYES</a>) stock fell 10.93% to $8.4. The current volume of 3.2 million shares is 13.51% of Second Sight Medical&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The market value of their outstanding shares is at $234.3 million.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) stock fell 10.0% to $13.69. Trading volume for this security as of 12:32 EST is 202, which is 0.41% of its average full-day volume over the last 100 days.</li>
</ul>

&nbsp;

&nbsp;

Intraday Update

12 Health Care Stocks Moving In Wednesday's Intraday Session

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>180 Life Sciences (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) shares increased by 27.31% to $12.4 during Monday&#39;s regular session. Trading volume for 180 Life Sciences&#39;s stock is 29.3 million as of 12:32 EST. This is 1203.77% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $298.5 million.</li>
	<li>Evelo Biosciences (NASDAQ:<a class="ticker" href="/stock/EVLO#NASDAQ">EVLO</a>) shares rose 22.06% to $12.26. As of 12:32 EST, this security is trading at a volume of 1.4 million shares, making up 563.83% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $653.6 million.</li>
	<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="/stock/TSHA#NASDAQ">TSHA</a>) stock rose 19.91% to $25.41. Trading volume for this security as of 12:32 EST is 442.3K, which is 591.28% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $959.5 million.</li>
	<li>Auris Medical Holding (NASDAQ:<a class="ticker" href="/stock/EARS#NASDAQ">EARS</a>) stock rose 16.0% to $5.0. Auris Medical Holding&#39;s stock is trading at a volume of 40.8 million shares as of 12:32 EST. This is 1050.22% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $64.3 million.</li>
	<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="/stock/TLSA#NASDAQ">TLSA</a>) shares rose 13.1% to $3.02. As of 12:32 EST, Tiziana Life Sciences&#39;s stock is trading at a volume of 3.1 million, which is 320.73% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $293.8 million.</li>
	<li>Luminex (NASDAQ:<a class="ticker" href="/stock/LMNX#NASDAQ">LMNX</a>) stock increased by 11.83% to $36.85. As of 12:32 EST, Luminex&#39;s stock is trading at a volume of 14.9 million, which is 2312.0% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.7 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>iRhythm Technologies (NASDAQ:<a class="ticker" href="/stock/IRTC#NASDAQ">IRTC</a>) stock fell 37.54% to $82.93 during Monday&#39;s regular session. The current volume of 4.6 million shares is 762.77% of iRhythm Technologies&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The company&#39;s market cap stands at $2.4 billion.</li>
	<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="/stock/GLSI#NASDAQ">GLSI</a>) stock decreased by 22.77% to $41.4. Greenwich LifeSciences&#39;s stock is trading at a volume of 1.0 million shares as of 12:32 EST. This is 169.54% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $531.8 million.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) shares fell 22.04% to $11.86. Biophytis&#39;s stock is trading at a volume of 5.8K shares as of 12:32 EST. This is 12.72% of its average full-day volume over the last 100 days.</li>
	<li>BriaCell Therapeutics (NASDAQ:<a class="ticker" href="/stock/BCTX#NASDAQ">BCTX</a>) stock declined by 16.94% to $4.33. As of 12:32 EST, BriaCell Therapeutics&#39;s stock is trading at a volume of 3.2 million, which is 278.46% of its average full-day volume over the last 100 days.</li>
	<li>Checkmate Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>) stock decreased by 16.09% to $8.87. Checkmate Pharmaceuticals&#39;s stock is trading at a volume of 37.0K shares as of 12:32 EST. This is 85.47% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $191.7 million.</li>
	<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/PIRS#NASDAQ">PIRS</a>) shares fell 15.93% to $2.34. The current volume of 1.1 million shares is 231.22% of Pieris Pharmaceuticals&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The company&#39;s market cap stands at $139.5 million.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Monday's Intraday Session

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 12)

<ul>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) (<a href="https://www.benzinga.com/news/21/04/20581755/why-ikena-oncology-evelo-biosciences-and-180-life-sciences-are-rallying-today">moved </a> on insider buying)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Fortress Biotech, Inc. (NASDAQ:<a class="ticker" href="/stock/FBIO#NASDAQ">FBIO</a>)</li>
	<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GANX#NASDAQ">GANX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MDXG#NASDAQ">MDXG</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 12)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/ACAD#NASDAQ">ACAD</a>)</li>
	<li>Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/ACHL#NASDAQ">ACHL</a>) (reacted to presentation at the American Association of Cancer Research annual meeting)</li>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>)</li>
	<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>)</li>
	<li>Adagene Inc. (NASDAQ:<a class="ticker" href="/stock/ADAG#NASDAQ">ADAG</a>)</li>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>) (reacted to AACR presentation)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASAQ: CFRX)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>) (moved on AACR presentation)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>) (reacted to preclinical data presented at AACR meeting)</li>
	<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>) (<a href=" https://www.benzinga.com/general/biotech/21/04/20573957/why-is-qualigen-stock-trading-lower-today">withdrew </a> emergency use authorization application for COVID-19 diagnostic test)</li>
	<li>Reata Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RETA#NASDAQ">RETA</a>)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) (went public&nbsp;Friday)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SYRS#NASDAQ">SYRS</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>) (went public Friday)</li>
	<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMAB#NASDAQ">YMAB</a>) (presented clinical data at AACR meeting)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Amarin Names Insider Karim Mikhail As CEO</h3>

Amarin Corporation plc (NASDAQ:<a class="ticker" href="/stock/AMRN#NASDAQ">AMRN</a>) announced that CEO John Thero has informed the board of directors of his plan to retire from the position of CEO&nbsp;effective Aug. 1. He will also step down from the board at that time.

The board has appointed Karim Mikhail, Amarin&#39;s senior SVP and head of commercial for Europe, to succeed Thero as the company&#39;s next president and CEO and as a board member. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021, the company said.

The stock was down 2.74% premarket at $5.68.&nbsp;

<h3>Johnson &amp; Johnson&#39;s Vaccine Use Paused By FDA</h3>

The Food and Drug Administration and the Centers for Disease Control and Prevention are <a href="https://www.benzinga.com/general/biotech/21/04/20595814/fda-recommends-pause-in-use-of-johnson-johnsons-covid-19-vaccine-on-blood-clot-concerns">recommending a pause</a> in the use of Johnson &amp; Johnson&#39;s (NYSE:<a class="ticker" href="/stock/JNJ#NYSE">JNJ</a>) COVID-19 vaccine due to reports of a rare type of blood clots.

The stock was down 2.68% at $157.30 in premarket trading Tuesday.

<h3>Roche Snags&nbsp;FDA Approval For Self-Injectable, Prefilled Syringe For Asthma Drug</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) said the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for Xolair, a prefilled syringe for self-injection across all approved U.S. indications.

Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria and nasal polyps.

<h3>Immunocore Presents Positive Phase 3 Data For Eye Cancer Drug</h3>

Immunocore presented at the AACR annual meeting with&nbsp;data from a Phase 3 trial comparing tebentafusp with investigator&#39;s choice, in first-line metastatic uveal melanoma, showing tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment for the condition.&nbsp;Treatment-related adverse events were manageable and consistent with the proposed mechanism.

The stock rose 3.57% to $33.37 in after-hours trading.

<h3>Burning Rock Biotech&#39;s Liquid Biopsy Assay Performs Strongly In&nbsp;Midstage Study</h3>

Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="/stock/BNR#NASDAQ">BNR</a>) announced the publication in Nature Biotechnology of results from a FDA-led Sequencing Quality Control Phase 2 study.

The data shows the liquid biopsy assay has achieved strong performance. For samples at a 25ng input, Burning Rock&#39;s assay was the most accurate assay, with roughly equivalent sensitivity but superior precision compared to other assays, the company said.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20567086/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentatio"> The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight </a>

<h3>Lilly-Innovent Presents Positive Late-Stage Tyvyt Data&nbsp;In Second-Line Lung Cancer Setting</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) and Hong Kong-based partner Innovent Biologics presented at the AACR annual meeting with results of the Phase 3 ORIENT-3 study evaluating Tyvyt versus the&nbsp; chemotherapy medication docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer.

The presentation shows that Tyvyt demonstrated a statistically significant improvement in overall survival compared to docetaxel, meeting the pre-specified primary endpoint.

The median progression-free survival as assessed by investigators was 4.3&nbsp;months versus 2.79 months, and the confirmed objective response rate was 25.5% versus 2.2%, respectively. Safety was consistent with previous studies of Tyvyt and no new safety signals were identified.

<h3>Tiziana to Seek Nasdaq Listing For Former Subsidiary Accustem</h3>

Tiziana Life Sciences PLC (NASDAQ:<a class="ticker" href="/stock/TLSA#NASDAQ">TLSA</a>) announced that its former subsidiary&nbsp;Accustem Sciences Limited&nbsp;intends to file a listing application with the Nasdaq after completion of the distribution of shares in Accustem to Tiziana shareholders.

The Nasdaq listing venue is more appropriate to the nature of Accustem&#39;s business in the view of Accustem&#39;s board.&nbsp;

The stock was trading 0.69% higher at $706.80 premarket Tuesday.

<h3>Offerings</h3>

Liquidia Corporation (NASDAQ:<a class="ticker" href="/stock/LQDA#NASDAQ">LQDA</a>) said it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8.626 million shares of common stock at a purchase price of $2.52 per share. The private placement is expected to close Tuesday and yield gross proceeds of approximately $21.7 million.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Affimed N.V. (NASDAQ:<a class="ticker" href="/stock/AFMD#NASDAQ">AFMD</a>) will present at the AACR annual meeting initial clinical data from an investigator-sponsored Phase 1 study evaluating cord blood-derived natural killercells pre-complexed with Affimed&#39;s innate cell engager AFM13. The company&#39;s shares reacted positively Friday&nbsp;when the company released a statement elaborating on data from the study.

Auris Medical Holding Ltd. (NASDAQ:<a class="ticker" href="/stock/EARS#NASDAQ">EARS</a>) is scheduled to provide a business update on its pre-clinical asset AM-301. AM-301 is being evaluated for protection against airborne viruses and allergens.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>MyMD Pharmaceuticals, Inc. - Common Stock (NASDAQ:<a class="ticker" href="/stock/MYMD#NASDAQ">MYMD</a>) shares moved upwards by 14.12% to $5.1 during Tuesday&#39;s regular session. As of 12:31 EST, this security is trading at a volume of 6.4 million shares, making up 1423.66% of its average full-day volume over the last 100 days.</li>
	<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/RXRX#NASDAQ">RXRX</a>) stock moved upwards by 12.53% to $31.51. Trading volume for this security as of 12:31 EST is 311.0K, which is 9.28% of its average full-day volume over the last 100 days.</li>
	<li>Purple Biotech (NASDAQ:<a class="ticker" href="/stock/PPBT#NASDAQ">PPBT</a>) stock moved upwards by 11.13% to $4.26. Trading volume for this security as of 12:31 EST is 600.5K, which is 71.15% of its average full-day volume over the last 100 days.</li>
	<li>Sharps Compliance (NASDAQ:<a class="ticker" href="/stock/SMED#NASDAQ">SMED</a>) shares moved upwards by 10.27% to $14.92. As of 12:31 EST, Sharps Compliance&#39;s stock is trading at a volume of 253.0K, which is 180.84% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $246.3 million.</li>
	<li>180 Life Sciences (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) stock rose 10.2% to $9.18. Trading volume for this security as of 12:31 EST is 596.6K, which is 18.82% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $220.9 million.</li>
	<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="/stock/SRTS#NASDAQ">SRTS</a>) stock increased by 7.35% to $3.65. Trading volume for this security as of 12:31 EST is 3.6K, which is 0.74% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $60.1 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="/stock/SNDX#NASDAQ">SNDX</a>) shares declined by 27.97% to $13.96 during Tuesday&#39;s regular session. The current volume of 5.1 million shares is 732.44% of Syndax Pharmaceuticals&#39;s average full-day volume over the last 100 days (last updated at 12:31 EST). The market value of their outstanding shares is at $673.3 million.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>) stock fell 14.41% to $11.77. As of 12:31 EST, Biophytis&#39;s stock is trading at a volume of 2.1K, which is 5.32% of its average full-day volume over the last 100 days.</li>
	<li>Clover Health Investments (NASDAQ:<a class="ticker" href="/stock/CLOV#NASDAQ">CLOV</a>) shares fell 11.54% to $8.55. Trading volume for Clover Health Investments&#39;s stock is 30.6 million as of 12:31 EST. This is 129.27% of its average full-day volume over the last 100 days.</li>
	<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="/stock/CMMB#NASDAQ">CMMB</a>) stock declined by 11.2% to $30.63. Trading volume for Chemomab Therapeutics&#39;s stock is 105.7K as of 12:31 EST. This is 38.49% of its average full-day volume over the last 100 days.</li>
	<li>Ardelyx (NASDAQ:<a class="ticker" href="/stock/ARDX#NASDAQ">ARDX</a>) shares fell 11.08% to $7.83. As of 12:31 EST, this security is trading at a volume of 2.9 million shares, making up 193.59% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $772.6 million.</li>
	<li>PainReform (NASDAQ:<a class="ticker" href="/stock/PRFX#NASDAQ">PRFX</a>) shares declined by 10.48% to $3.16. PainReform&#39;s stock is trading at a volume of 44.0K shares as of 12:31 EST. This is 21.07% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $31.7 million.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Tuesday's Intraday Session

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares moved upwards by 16.01% to $10.72 during Wednesday&#39;s regular session. The current volume of 64.6 million shares is 267.84% of Clover Health Investments&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST).</li>
	<li>Akouos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKUS#NASDAQ">AKUS</a>) stock increased by 14.82% to $16.11. Trading volume for this security as of 12:32 EST is 120.1K, which is 50.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $554.2 million.</li>
	<li>MIND MEDIC SUB VT SH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) shares moved upwards by 14.46% to $4.6. As of 12:32 EST, this security is trading at a volume of 15.3 million shares, making up 25.05% of its average full-day volume over the last 100 days.</li>
	<li>Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) stock increased by 13.31% to $2.22. Atossa Therapeutics&#39;s stock is trading at a volume of 8.9 million shares as of 12:32 EST. This is 55.57% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $268.3 million.</li>
	<li>VistaGen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>) stock increased by 10.84% to $2.35. Trading volume for VistaGen Therapeutics&#39;s stock is 2.0 million as of 12:32 EST. This is 66.98% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $446.9 million.</li>
	<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock rose 10.4% to $1.91. As of 12:32 EST, this security is trading at a volume of 6.8 million shares, making up 459.74% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $267.0 million.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) stock fell 19.03% to $34.57 during Wednesday&#39;s regular session. As of 12:32 EST, this security is trading at a volume of 2.4 million shares, making up 427.51% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.5 billion.</li>
	<li>Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) shares fell 18.84% to $27.27. As of 12:32 EST, this security is trading at a volume of 3.3 million shares, making up 895.24% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 billion.</li>
	<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock declined by 15.28% to $18.21. Trading volume for BioVie&#39;s stock is 191.4K as of 12:32 EST. This is 179.44% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $253.4 million.</li>
	<li>Nymox Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMX#NASDAQ">NYMX</a>) stock fell 13.83% to $2.12. The current volume of 989.9K shares is 433.74% of Nymox Pharmaceutical&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST). The company&#39;s market cap stands at $166.8 million.</li>
	<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 11.65% to $6.45. As of 12:32 EST, this security is trading at a volume of 789.2K shares, making up 53.86% of its average full-day volume over the last 100 days.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock declined by 10.0% to $13.5. The current volume of 294 shares is 0.81% of Biophytis&#39;s average full-day volume over the last 100 days (last updated at 12:32 EST).</li>
</ul>

&nbsp;

&nbsp;

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 28)

<ul>
	<li>Axonics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXNX#NASDAQ">AXNX</a>)</li>
	<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) (reacted to first-quarter results)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Celldex Therapeutics, Inc. (NASDAQ:&nbsp;CLDX)</li>
	<li>Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>)</li>
	<li>Horizon Therapeutics Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HZNP#NASDAQ">HZNP</a>)</li>
	<li>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) (announced first-quarter results)</li>
	<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>NuVasive, Inc. (NASDAQ:&nbsp;NUVA)</li>
	<li>PRA Health Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAH#NASDAQ">PRAH</a>)</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAV#NASDAQ">SWAV</a>)</li>
	<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 28)

<ul>
	<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>IRadimed Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRMD#NASDAQ">IRMD</a>)</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>)</li>
	<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>)</li>
	<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>)</li>
	<li>PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Adverum Shares Sink On Serious Adverse Event&nbsp;</h3>

Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.

This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

Adverum said it has decided to immediately unmask the INFINITY Phase 2 study to better understand this event and to help identify and manage any similar potential risk to other patients in this study. Additionally, the company is conducting a thorough review of data from the ADVM-022 program and plans to report its findings as the analysis progresses.

The stock was down 52.17% to $4.86 in after-hours trading.

<h3>Galera Reports Positive Updated Results For Phase 1/2 Pancreatic Cancer Study</h3>

Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) announced updated results from its Phase 1/2 pilot trial of GC4419, versus placebo, in patients with locally advanced pancreatic cancer&nbsp;who are undergoing stereotactic body radiation therapy.

The updated results, as of the data analysis, include a minimum follow up of six months on all 42 patients and were consistent with the positive results reported with a minimum follow up of three months, the company said.

Galera said it plans to report final results from the trial after a minimum of one year of follow up, expected during the second half of 2021.

In after-hours trading, the stock was up 30.11% at $8.60.

<h3>Akebia Announces Publication Of Positive Phase 3 Study Results For Lead Drug to Treat Anemia In CKD Patients</h3>

Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) announced publication in the New England Journal of Medicine results of the global Phase 3 clinical program of its lead candidate vadadustat for the treatment of anemia due to chronic kidney disease in adult patients on dialysis and adult patients not on dialysis in two separate manuscripts.

Among patients with anemia and CKD who were undergoing dialysis, vadadustat was non-inferior to Amgen, Inc.&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Aranesp with respect to cardiovascular safety and maintenance of hemoglobin concentrations, while in patients not undergoing dialysis, vadadustat met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety.

Akebia shares were up 7.5% to $3.44 in after-hours trading.

<h3>Biogen&#39;s Multiple Sclerosis Drug Fails To Win&nbsp;Label Expansion&nbsp;</h3>

Biogen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said it has received a complete response letter from the FDA for its supplemental biologic license application for a new subcutaneous route of administration of Tysabri to treat relapsing multiple sclerosis. Biogen said is evaluating the CRL and will determine next steps in the U.S.

The stock lost 1.35% to $264 in after-hours trading.

<h3>Cara Announces Mixed Results In&nbsp;Atopic Dermatitis Study</h3>

Cara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) announced mixed topline results from its KARE Phase 2 dose-ranging clinical trial of oral Korsuva for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients.

The company said the study did not meet the primary endpoint of worst-itch NRS change from baseline at week 12 or secondary endpoint of 4-point responder analysis in the intent-to-treat patient population. However, the study achieved primary endpoint of worst-itch NRS change and secondary endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients, comprising 64% of ITT population.

The stock was down 18.57% to $4.79 in premarket trading Thursday.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20779951/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx">The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx </a>

<h3>Flexion To Present Positive Phase 1 Data For Gene Therapy Candidate In Osteoarthritis</h3>

Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#NASDAQ">FLXN</a>) said it will present at the 2021 American Society of Gene &amp; Cell Therapy annual meeting, preliminary data from a Phase 1 single ascending dose trial of FX201, showing the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis, was generally well-tolerated.

The company also said two of five patients treated with FX201 in the low-dose, single ascending dose cohort reported substantial improvement in pain out to week 24. There was no evidence of systemic biodistribution of FX201 in plasma or shedding in urine or at the injection site was observed in any patient.

The stock was up 5.01% to $8.60 in after-hours trading.

<h3>Lucira Health Announces Increase In COVID-19&nbsp;Test Kit Production Capacity With Opening of Partner Jabil&#39;s New Facility</h3>

Lucira Health, Inc. (NASDAQ: LHDX announced the opening of a new production center in the Dominican Republic by its manufacturing partner Jabil Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jbl#NYSE">JBL</a>).

The new facility will increase production of the LUCIRA CHECK IT COVID-19 test kit during the second quarter of 2021. Jabil also manufactures <a href="https://www.benzinga.com/general/biotech/21/04/20534033/3-stocks-near-52-week-lows-that-could-bounce-back">Lucira&#39;s </a>unique COVID-19 test in Auburn Hills, Michigan.

Lucira shares were up 1.6% to $7 in premarket trading Thursday.

<h3>Biophytis Secures $1.19M Non-Dilutive Funding For Eye Disorder Program</h3>

Biophytis SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) said it was granted a non-dilutive funding of 980,000 euros ($1.19 million) from the public investment bank BPI France&#39;s DeepTech program, for its Macuneos in dry age-related macular degeneration.

Macuneos is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. The company said it plans to initiate a Phase 1 clinical trial in healthy volunteers in the second half of 2021.

<h3>Can-Fite Says 75% Enrollment Completed In Late-Stage Psoriasis Study</h3>

Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) announced that 75% of patients have been enrolled in its Phase 3 Comfort study designed to establish piclidenoson&#39;s superiority compared to placebo and non-inferiority compared to Otezla in patients with moderate to severe plaque psoriasis.

The company said it expects to complete enrollment in the third quarter and report topline results in the fourth quarter.

The stock rose 5.5% to $2.30 in premarket trading Thursday.

<h3>Moderna to Invest In Bid To&nbsp;Boost COVID-19 Vaccine Capacity&nbsp;</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced it is making new funding commitments to increase supply at its owned and partnered manufacturing facilities. The company said this will increase global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine, depending upon the mix between the <a href="https://www.benzinga.com/general/biotech/20/12/18864205/moderna-finishes-the-vaccine-race-close-behind-pfizer-as-fda-authorizes-its-coronavirus-vaccine-f">authorized Moderna COVID-19 vaccine </a> at the 100 &mu;g dose level and potentially lower doses of the company&#39;s variant booster candidates and pediatric vaccines, if authorized.

The company plans to use its cash balance to fund these investments.

The company also increased its 2021 supply forecast to between 800 million and 1 billion doses. Additionally, it announced data supporting three-month refrigerated (2-8&deg;C) stable formulation.

<h3>Earnings</h3>

Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) said its second-quarter revenues climbed 103.4% year-over-year to $1.538 billion, and non-GAAP EPS came in at $2.59, trailing the consensus estimate of $2.62 per share.

For the third quarter, the company guided to revenues of $1 billion to $1.07 billion and non-GAAP EPS to $1-$1.15. The guidance was also below estimates.

The stock was down 6.77% at $67.50 in after-hours trading.

Alimera Sciences, Inc.&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) first-quarter net revenues fell 23% to $11.2 million and the net loss per share widened from 24 cents to 63 cents. Analysts had expected a smaller loss of 54 cents per share.

The stock moved down 4.95% to $10.75 in after-hours trading.

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) reported a wider loss of 19 cents per share for the first quarter compared to a loss of 13 cents per share a year ago. Analysts, on average, had estimated a loss of 17 cents per share.

The stock pulled back 4.87% to $6.05 in after-hours trading.

MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) reported a decline in first-quarter sales and a wider loss.

In after-hours trading, the stock lost 5.32% to $10.14.

<h3>On The Radar</h3>

<h3>PDUFA Dates</h3>

The FDA is scheduled to announced its decision on Ardelyx, Inc.&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) NDA for tenapanor in hyperphosphatemia.

<h3>Earnings</h3>

<ul>
	<li>Syneos Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNH#NASDAQ">SYNH</a>) (before the market open)</li>
	<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) (before the market open)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) (before the market open)</li>
	<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) (before the market open)</li>
	<li>Evelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLO#NASDAQ">EVLO</a>) (before the market open)</li>
	<li>Baxter International Inc. BAX) (before the market open)</li>
	<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) (before the market open)</li>
	<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) (before the market open)</li>
	<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) (before the market open)</li>
	<li>Laboratory Corporation of America Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) (before the market open)</li>
	<li>Abiomed, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABMD#NASDAQ">ABMD</a>) (before the market open)</li>
	<li>Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) (before the market open)</li>
	<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) (before the market open)</li>
	<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) (after the close) (after the close)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) (after the close)</li>
	<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) (after the close)</li>
	<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) (after the close)</li>
	<li>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) (after the close)</li>
	<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) (after the close)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCXI#NASDAQ">CCXI</a>) (after the close)</li>
	<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) (after the close)</li>
	<li>Gilead Sciences, Inc. (NASDAQ:&nbsp;GILD) (after the close)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) (after the close)</li>
	<li>LeMaitre Vascular, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) (after the close)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) (after the close)</li>
	<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) (after the close)</li>
	<li>Seagen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGEN#NASDAQ">SGEN</a>) (after the close)</li>
</ul>

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx

&nbsp;

<h3>Gainers</h3>

<ul>
	<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares rose 46.68% to $11.28 during Thursday&#39;s regular session. As of 12:30 EST, Rezolute&#39;s stock is trading at a volume of 1.4 million, which is 7155.42% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $94.2 million.</li>
	<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock increased by 17.62% to $6.58. Trading volume for this security as of 12:30 EST is 5.5 million, which is 543.46% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $406.7 million.</li>
	<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) stock increased by 17.37% to $9.39. Trading volume for this security as of 12:30 EST is 753.3K, which is 242.14% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $221.5 million.</li>
	<li>Pieris Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIRS#NASDAQ">PIRS</a>) stock moved upwards by 17.11% to $3.97. Pieris Pharmaceuticals&#39;s stock is trading at a volume of 23.9 million shares as of 12:30 EST. This is 293.43% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $231.4 million.</li>
	<li>Zosano Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSAN#NASDAQ">ZSAN</a>) stock increased by 15.59% to $0.86. As of 12:30 EST, this security is trading at a volume of 14.9 million shares, making up 542.51% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $91.7 million.</li>
	<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares increased by 14.81% to $22.4. Lantheus Holdings&#39;s stock is trading at a volume of 4.1 million shares as of 12:30 EST. This is 635.27% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 billion.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

&nbsp;

<ul>
	<li>NextGen Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGN#NASDAQ">NXGN</a>) shares fell 14.29% to $16.05 during Thursday&#39;s regular session. As of 12:30 EST, this security is trading at a volume of 788.8K shares, making up 289.52% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $1.0 billion. As per the news, the Q4 earnings report came out yesterday.</li>
	<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 10.04% to $2.42. As of 12:30 EST, this security is trading at a volume of 1.0 million shares, making up 11.16% of its average full-day volume over the last 100 days. The company&#39;s market cap stands at $35.4 million.</li>
	<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock decreased by 9.12% to $10.97. Trading volume for this security as of 12:30 EST is 167, which is 6.98% of its average full-day volume over the last 100 days.</li>
	<li>Oak Street Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSH#NYSE">OSH</a>) stock decreased by 7.97% to $59.59. The current volume of 4.8 million shares is 285.88% of Oak Street Health&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $14.3 billion.</li>
	<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares fell 7.78% to $1.66. The current volume of 1.8 million shares is 239.01% of Kintara Therapeutics&#39;s average full-day volume over the last 100 days (last updated at 12:30 EST). The company&#39;s market cap stands at $54.1 million.</li>
	<li>AnPac Bio-Medical Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPC#NASDAQ">ANPC</a>) stock decreased by 7.38% to $4.52. Trading volume for AnPac Bio-Medical Science&#39;s stock is 682.2K as of 12:30 EST. This is 61.05% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $57.2 million. The company&#39;s, Q1 earnings came out today.</li>
</ul>

&nbsp;

&nbsp;

12 Health Care Stocks Moving In Thursday's Intraday Session

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs May 27)

<ul>
	<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) (<a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/05/21323220/forget-amc-gamestop-analyst-names-2-new-reddit-stocks-traders-should-watch">propped up </a> by retail buying frenzy)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>I-Mab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>)</li>
	<li>PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>)</li>
	<li>PLx Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXP#NASDAQ">PLXP</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows May 27)

<ul>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>IMV Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMV#NASDAQ">IMV</a>)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>)</li>
	<li>Valneva SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Iterum Says FDA Regulatory Review Of Investigational Urinary Tract Infection Treatment On Track</h3>

Iterum Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) announced that it participated in a late-cycle meeting with the FDA and said it responded to all issues raised by the agency regarding the new drug application for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen.

The FDA has determined that an Advisory Committee meeting is not currently necessary. The review of the NDA is ongoing, and the FDA said it continues to work toward the PDUFA goal date of July 25.

The stock jumped 25.2% to $1.54 in after-hours trading.

<h3>Provention&#39;s Type 1 Diabetes Drug Wins Adcom Backing; Delay Likely In Approval Due To Previously Communicated Issues</h3>

Provention Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVB#NASDAQ">PRVB</a>) said the Endocrinologic and Metabolic Drugs Advisory Committee voted 10-7 in favor of the benefits of teplizumab outweighing the risks in support of approval to delay clinical type 1 diabetes mellitus. The PDUFA action date is July 2.

The previously <a href="https://www.benzinga.com/general/biotech/21/04/20552835/provention-bio-stock-craters-after-fda-flags-deficiencies-in-pk-profiles-from-teplizumab-trials-f">disclosed </a> matter surrounding pharmacokinetic comparability was not a topic for discussion during the Adcom meeting. The company reiterated its previous guidance that the FDA&#39;s PK comparability considerations are likely to result in a delay in potential biologic license approval timelines.

<h3>Biohaven&#39;s Migraine Drug Approved As&nbsp;Both Preventive, Treatment Option</h3>

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) announced FDA approval of Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. It is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.

The approved product label was also expanded to include the use of Nurtec ODT 75 mg up to 18 doses/month, allowing for both acute and preventive therapy in the same patient.

In after-hours trading, the stock rose 2.68% to $84.75.

<h3>Fennec Resubmits Regulatory Application For Drug to Treat Ototoxicity Induced By Chemotherapy In Kids, Adolescents</h3>

Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) announced the resubmission of its NDA for Pedmark, a unique formulation of sodium thiosulfate, for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to less than 18 years of age with localized, non-metastatic, solid tumors.

The resubmission follows receipt of final minutes from a Type A meeting with the FDA.

The complete response letter issued by the FDA in August&nbsp;2020 referred to deficiencies with the facility of the drug product manufacturer, while no clinical safety or efficacy issues were identified and there was no requirement for further clinical data.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21247402/the-week-ahead-in-biotech-may-23-29-eton-lantheus-fda-decisions-adcom-test-for-provention-chiasma"> The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation </a>

<h3>Bristol-Myers Squibb&#39;s Zeposio Approved For Moderately to Severely Active Ulcerative Colitis</h3>

Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) announced FDA approval for Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.

&quot;We&#39;re thrilled that our pursuit of transformative science in immunology may benefit patients in their ulcerative colitis treatment by introducing a new option that has a different mechanism of action than available therapies. Zeposia combines disease control through lasting remission and demonstrated safety in a once-daily pill,&quot; said Adam Lenkowsky, general manager and head, U.S., Cardiovascular, Immunology and Oncology, at Bristol-Myers Squibb.

<h3>Revolution Medicines Moves Lower On Insider Selling</h3>

Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) disclosed in a filing Third Rock Ventures II, which has a seat in the company&#39;s board, offloaded 1,366,204 shares of the company. After the transaction, TRV II owned 1,774,317 shares of the company.

The stock slipped 2.19% to $29.51 in after-hours trading.

<h3>Lucira Health Appoints MedTech Veteran Kevin Collins As Chief Revenue Officer</h3>

Lucira Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHDX#NASDAQ">LHDX</a>) announced the appointment of MedTech veteran Kevin Collins as chief revenue officer with global revenue responsibility.

The stock was down 3.19% to $4.86 in premarket trading Friday.

<h3>On The Radar</h3>

<h3>IPOs</h3>

Centessa Pharmaceuticals plc, a clinical-stage biopharma, announced that it has priced its initial public offering of 16.5 million ADSs, each representing one ordinary share, at $20 per ADS. All of the ADSs are being offered by Centessa.

The gross proceeds to Centessa from the offering are expected to be approximately $330 millionThe shares are expected to begin trading on the Nasdaq under the ticker symbol &quot;CNTA.&quot;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/20890405/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates">Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates </a>

The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs June 8)

<ul>
	<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>)</li>
	<li>Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>)</li>
	<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) (announced 510(k) clearance for the device for the non-surgical removal of thrombi or emboli from the vasculature)</li>
	<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>)</li>
	<li>Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) (gained in the run up to data presentation)</li>
	<li>Dicerna Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRNA#NASDAQ">DRNA</a>)</li>
	<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)</li>
	<li>Oramed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORMP#NASDAQ">ORMP</a>) (announced over 50% enrollment in the Phase 3 study of its oral insulin capsule ORMD-0801 for type 2 diabetes)</li>
	<li>Paratek Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTK#NASDAQ">PRTK</a>)</li>
	<li>Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>)</li>
	<li>Sesen Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SESN#NASDAQ">SESN</a>)</li>
	<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows June 8)

<ul>
	<li>Angion Biomedica Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGN#NASDAQ">ANGN</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGTX#NASDAQ">SGTX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Lyra Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA Over Lead Drug For The Treatment of Chronic Rhinosinusitis</h3>

Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) announced the successful outcome of an end-of-Phase 2 meeting with FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis.The company said along with the FDA it established key elements of the Phase 3 program to support a 505(b)(2) new drug application for LYR-210 for the treatment of CRS.

The single primary endpoint will evaluate improvement at week 24 using a composite score of three cardinal symptoms of CRS: nasal blockage, nasal discharge, and facial pain. Based on the agency&#39;s suggestion, Lyra intends to enroll a total of approximately 350 subjects split into two replicate, largely concurrent Phase 3 clinical trials, each powered to &gt;95% to detect statistical significance. Both studies will evaluate a 7500&micro;g dose of LYR-210, and additional key clinical aspects of the studies will also be the same.

&quot;Following our successful End of Phase 2 meeting with the FDA, we believe that we have a clear path forward to advance LYR-210&#39;s clinical development for the treatment of CRS,&quot; the company said.

The stock gained 21.73% to $9.58 in after-hours trading.

<h3>Pfizer Announces FDA Approval For Vaccine Against 20 Strains of Bacteria</h3>

Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) said the FDA has approved Prevnar 20, Pneumococcal 20-valent Conjugate Vaccine, for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older.

Following the FDA approval, the U.S. Centers for Disease Control and Prevention&#39;s Advisory Committee on Immunization Practices is expected to meet in October to discuss and update recommendations on the safe and appropriate use of pneumococcal vaccines in adults.

<h3>Transmedics Announces Positive Results From Study of OCS Liver System That Preserves Donor Organs</h3>

TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) announced that the complete results of the OCS Liver PROTECT Trial were presented virtually at the American Transplant Congress, showing the study met its primary effectiveness endpoint and demonstrated a significant reduction in early allograft dysfunction with OCS.

OCS preserved livers also demonstrated a significant reduction in histopathological evidence of IR injury after reperfusion and significant attenuation of reperfusion syndrome in the recipient. OCS use was also associated with significant reduction of ischemic biliary complications at one year, a leading cause of graft failure after liver transplant.

The stock rallied 9.35% to $28.90 in after-hours trading.

<h3>SQZ to Present Positive Pre-clinical Results For Autoimmune Diseases Program</h3>

SQZ Biotechnologies Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQZ#NYSE">SQZ</a>) said it is presenting preclinical results from the Tolerizing Antigen Carrie &ndash; TAC - program demonstrating that its engineered TACs can drive antigen-specific immune tolerance through key mechanisms relevant to many complex autoimmune diseases.

In models of Type 1 diabetes, SQZ TACs were able to delete antigen-specific T cells, without causing non-specific immune suppression, ultimately preventing hyperglycemia. Importantly, SQZ TACs increased antigen-specific regulatory T cells that exerted potent bystander suppression, showing the ability to suppress pathogenic T cells with different autoantigen specificities. Together, these results suggest that SQZ TACs are a versatile platform for inducing antigen-specific immune tolerance, the company said.

The data will be presented Thursday at the 2021 Federation of Clinical Immunology Sciences annual meeting.

The stock was up 2.54% to $13.74% in premarket trading Wednesday.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/05/21351378/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-limi"> Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates</a>

<h3>Merck Agrees to Supply COVID Treatment to U.S.</h3>

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) announced it has entered into a procurement agreement with the U.S. government for molnupiravir. <a href="https://www.benzinga.com/general/biotech/21/03/20050140/merckridgeback-biotherapeutics-covid-19-antiviral-shows-promise">Molnupiravir </a> is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

Merck shares were up 0.76% at $72.96 in premarket trading Wednesday.

<h3>Sonnet Gets U.S. Patent For Technology Targeting Tumors</h3>

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) said the U.S. Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 11,028,166 entitled, &quot;Albumin Domain Fusion Proteins.&quot;The patent covers Sonnet&#39;s Fully Human Albumin Binding technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention and provide extended pharmacokinetics, and the patent carries a term effective until March 2039.

The stock moved up 7.19% to $1.64 in after-hours trading.

<h3>Kiniksa Issued U.S. Patent For Rilonacept To Treat Swelling of Heart Membrane</h3>

Kiniksa Pharmaceuticals, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) announced that the USPTO issued a patent covering methods of using Arcalyst (rilonacept) in the treatment of recurrent pericarditis.The patent issued will expire on March 11, 2039. Kiniksa has exclusive rights to this patent under the Arcalyst License Agreement.

The stock rose 2.18% to $14.50 in after-hours trading.

<h3>Offerings</h3>

Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) said it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. The company <a href="https://www.benzinga.com/general/biotech/21/06/21468325/aclaris-ati-1777-aces-atopic-dermatitis-trial-with-minimal-systemic-exposure">reported </a> Tuesday positive preliminary results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis

<h3>On The Radar</h3>

<h3>Clinical Readouts/Presentations</h3>

Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) will hold a webinar at 11 am to release and discuss final data from its Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery.

The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US

Q1 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-06-25
REV		(EXPECTED)2021-06-25

Recent Quotes

Earnings

Related Companies

Biophytis Frequently Asked Questions

How do I buy Biophytis (BPTS) stock?

Who are Biophytis's (BPTS) competitors?

What is the target price for Biophytis (BPTS) stock?

Current Stock Price for Biophytis (BPTS)?

Does Biophytis (BPTS) pay a dividend?

When is Biophytis (NASDAQ:BPTS) reporting earnings?

Is Biophytis (BPTS) going to split?

What sector and industry does Biophytis (BPTS) operate in?